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Summary 
 1 
Summary 
 
Prions are proteinaceous infectious agents that replicate by recruiting and converting 
homotypic soluble proteins into growing aggregates. Prions in mammals cause 
transmissible spongiform encephalopthies and are composed of membrane-bound 
PrP. In addition to prions in mammals, infectious protein aggregates were also 
identified in lower eukaryotes. Prion domains of lower eukaryotes are often enriched 
in glutamine (Q) and asparagine (N) residues and are usually located in unstructured 
regions. Interestingly, approximately one percent of human protein-coding genes 
contain Q/N rich prion-like domains. Until recently, it was unclear if prion replication is 
possible in the mammalian cytosol. By expressing the prion domain of 
Saccharomyces cerevisiae Sup35 in mouse neuroblastoma cells, our group could 
already show that Q/N rich prions can replicate in the mammalian cytosol. Yet, which 
regions within the Q/N rich prion domain of Sup35 specifically drive prion induction, 
propagation and inheritance in mammalian cells was so far unclear. Therefore, the 
aim of this study was to identify the essential regions that are required for the 
individual steps of prion replication in the mammalian cytosol. Surprisingly, we found 
that the aminoterminal region essential for prion activity in yeast, was dispensable for 
prion replication in the mammalian cytosol and even helped to retain the protein in its 
soluble state. Instead, we identified a carboxyterminal region with a lower Q/N 
content as the crucial region for prion replication in mammalian cells, a region that 
was shown not to influence prion formation in yeast. Interestingly, we found that in 
mammalian cells all prion activity was governed by only one distinct region, whereas 
in yeast, prion replication processes were depending on separate elements. 
Combined, these findings indicate that prion domains active in mammalian cells differ 
from the ones active in yeast, and suggest that studies on prionogenic behavior of 
prion or prion-like proteins should be undertaken in the correct environment. Our data 
provides a more detailed insight into the requirements for cytosolic prion replication in 
the mammalian cytosol, and will help to better predict proteins with prion-like 
properties that might be the cause for diseases of so far unknown etiology in 
mammals.
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1.Introduction 
 
1.1 Prion diseases 
 
Prions were first described by Stanly Prusiner in 1982 as the causative agent for 
prion diseases, also known as transmissible spongiform encephalopathies (TSEs). 
Prions are proteinaceous infectious particles that replicate independently of nucleic 
acids (Prusiner 1982). In his protein-only hypothesis, Prusiner postulates that the 
cellular prion protein (PrPC) undergoes a post-translational conformational change to 
its misfolded isoform (PrPSc) that serves as a template for continuous conversion of 
further cellular PrPC monomers (Griffith 1967, Prusiner 1998). TSEs are fatal 
neurodegenerative disorders that affect humans and other mammals. In humans they 
include Creutzfeldt-Jakob disease (CJD), variant CJD, fatal familial insomnia (FFI), 
Gerstmann-Sträussler-Scheinker syndrome (GSS) and kuru. Scrapie in goats and 
sheep, bovine spongiform encephalopathy (BSE) in cattle and chronic wasting 
disease (CWD) in deer and elk (Prusiner 1998), account for TSEs in mammals. Prion 
diseases can be acquired, as observed for kuru and variant CJD, sporadic, resulting 
from spontaneous conversion to the prion isoform, or familial, as a result of mutations 
in the PrP gene (PRNP). TSE pathology is characterized by the deposition of 
misfolded PrP aggregates in the central nervous system (CNS) and lymphoreticular 
system, as well as histopathological hallmarks such as neuronal vacuolation and 
degeneration (Prusiner 1998). Prion diseases have a very long incubation time 
before clinical symptoms are noticeable. They can be discriminated from other 
misfolding disorders through their unique infectivity and transmissibility within and 
between species (Aguzzi and Heikenwalder 2006). 
 
1.2 PrP: structure and replication  
 
PrP is encoded by the highly conserved PRNP gene, which shows more than 80 % 
sequence homology from amphibians to mammals (Basler et al. 1986). PrP 
expression was found in skeletal muscle, kidney, heart, secondary lymphoid organs 
and the CNS (Aguzzi and Heikenwalder 2006). So far, the cellular prion protein has 
been associated with a wide array of physiological functions, including signaling 
cascades, neuronal survival, apoptosis, immunomodulation and microRNA 
metabolism (Gibbings et al. 2012, Linden et al. 2012). PrP consists of 254 amino 
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acids (aa), has an aminoterminal signal peptide (SP) for endoplasmic reticulum (ER) 
translocation and is tethered to the outer leaflet of the plasma membrane by a 
carboxyterminal glycosylphosphatidylinositol (GPI) anchor (Fig. 1). 
 
 
 
 
 
Figure 1. Primary sequence of PrP. PrP consists of 254 amino acids and contains an ER 
signal peptide (SP, aa 1-22), an octapeptide repeat region (OR, aa 51-91), consisting of five 
octapeptide repeats, a hydrophobic core region (HC, aa 111-134), two glycosylation (Glc) 
sites (aa 181, 197) and a GPI anchor. Numbers refer to amino acids. 
 
The aminoterminal part of the protein is unstructured but contains two distinct 
regions: The octapeptide repeat region that consists of five oligopeptide repeats (OR, 
PHGGGWGQ, aa 51-91) and a downstream hydrophobic core region (HC,              
aa 111-134) (Aguzzi and Heikenwalder 2006). The carboxyterminal part of the 
protein is mainly α-helical and contains two glycosylation (Glc) sites. Replication of 
PrPSc occurs through the process of seeded polymerization (Come et al. 1993, 
Caughey et al. 1995) (Fig. 2).  
 
 
 
 
Figure 2. PrPSc replication by seeded polymerization. On rare occasions, PrPC monomers 
spontaneously convert to the misfolded isoform PrPSc via a PrP intermediate. PrPSc seeds 
subsequently serve as templates to bind and convert further PrPC monomers to the 
misfolded isoform. In secondary nucleation events, growing amyloid fibrils are fragmented 
into smaller entities that function as new conversion sites. 
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PrP is hypothesized to exist in equilibrium between PrPC and a PrP intermediate, 
where the PrPC monomer is favored. On rare occasions, PrPC undergoes a 
conformational change to its misfolded isoform PrPSc. Spontaneously formed 
misfolded conformers bind soluble PrPC monomers and template their conversion 
into the prion isoform, leading to continuously growing fibrils with so-called     
amyloid-structure. Amyloid fibrils have a distinct conformation. They are usually       
6-12 nm in diameter, rigid and non-branching (Serpell 2000, Serpell et al. 2000, 
Stefani and Dobson 2003). Each amyloid fibril consists of two to six protofilaments 
that are twisted around each other forming a supercoiled structure (Serpell 2000, 
Serpell et al. 2000, Stefani and Dobson 2003). Furthermore, each protofilament 
comprises a number of β-sheets that run perpendicular to the fibril axis (Shewmaker 
et al. 2008, Shewmaker et al. 2009). In secondary nucleation events, the growing 
amyloid fibril is fragmented into smaller infectious entities that function as new seeds 
for the conversion of further PrPC monomers (Orgel 1996, Knowles et al. 2009). 
Interestingly, Caughey and colleagues demonstrated in 2005, that non-fibrillar 
particles comprising 14-28 PrP molecules are the most infectious (Silveira et al. 
2005). In contrast to the mainly α-helical PrPC, PrPSc aggregates are rich in β-sheets, 
resulting in increased heat-, detergent- and protease-resistance. While PrPC is 
sensitive to proteinase K digestion, PrPSc contains a proteolytic protected 
carboxyterminal core (aa 90 – 231) (Prusiner et al. 1984, Oesch et al. 1985). The 
proteinase K resistance of PrPSc is broadly used to distinguish the two isoforms 
(Oesch et al. 1985, Gasset et al. 1992). 
 
1.3 The species barrier and prion strains 
 
Prions are transmissible within one species and sometimes also between species. 
However, in interspecies transmissions, usually prolonged incubation times are 
observed, known as the ‘’species barrier’’ (Bruce 1993, Bruce et al. 1994, Sweeting 
et al. 2010). The species barrier is predominantly determined by polymorphisms in 
PrP (Scott et al. 1993, Schatzl et al. 1995, Priola et al. 2001). The severity of the 
species barrier and the duration of incubation time can be highly variable, depending 
on the conformational degree of overlap between the infectious and normal prion 
protein (Collinge and Clarke 2007, Beringue et al. 2008). 
The existence of prion strains was first demonstrated in 1961 (Pattison and Millson 
1961). In 1992, Bessen and Marsh detected that strains isolated from outbred Syrian 
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golden hamsters differed in the biochemical and physical properties of PrPSc (Bessen 
and Marsh 1992). Prion strains differ in their incubation period as well as type, 
severity and distribution of pathological changes in the brain and are associated with 
a characteristic lesion profile (Fraser and Dickinson 1968, Bruce 1993). Additionally, 
prion strains exhibit differences in the biochemical properties of PrPSc, such as 
electrophoretic mobility of PrPSc after proteinase K digestion, stability towards 
denaturing agents and ratio of glycoforms (Beringue et al. 2008). Strain-specific 
phenotypes, including biochemical properties as well as pathology, are stably 
propagated from mouse to mouse (Telling et al. 1996, Beringue et al. 2008). In 2001, 
Soto and coworkers invented a new method for in vitro replication of prions, termed 
''Protein Misfolding Cyclic Amplification'' (PMCA). Using PMCA it was demonstrated 
that prion strain phenotypes are also stably propagated in vitro (Saborio et al. 2001, 
Castilla et al. 2005). However, the underlying mechanisms that result in the initial 
formation of diverse prion strains are still unknown. 
 
1.4 Protein misfolding diseases 
 
The conformational change from natively folded or unfolded protein into a misfolded 
isoform is not only observed for prion proteins. Proteins that exhibit prion-like 
properties are associated with many neurodegenerative diseases, including 
Alzheimer’s disease (AD), Parkinson’s disease (PD) and type 2 diabetes (Soto 
2012). The largest group among the protein misfolding diseases (PMDs) is 
associated with the formation of amyloid aggregates. Interestingly, even though 
these aggregation-prone proteins share the formation of this particular amyloidogenic 
molecular structure, they share no obvious sequence similarities (Chiti and Dobson 
2006). To date, a great number of proteins was shown to form amyloid conformations 
under specific conditions, arguing that the ability to form into an amyloid structure is a 
generic property of all proteins whose propensity can, however, vary depending on 
the sequence (Chiti and Dobson 2006). Similar to PrP, amyloids are formed by 
seeded polymerization. Interestingly, several disease-associated amyloids are, on a 
molecular und cellular level, also transmissible between cells (Walker and Jucker 
2015), and thus share some prion-like characteristics. Yet, in contrast to PrP, there is 
no epidemiological proof of transmission from one individual to another (Aguzzi and 
Rajendran 2009, Cushman et al. 2010). 
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1.5 Prions in lower eukaryotes 
 
Besides the mammalian prion protein, several proteins in lower eukaryotes have 
been identified that are capable of converting into a prion isoform (Table 1).  
 
Table 1. Prions in lower eukaryotes 
 
Protein Prion isoform Cellular function Reference 
Sup35 [PSI+] Translation termination (Wickner 1994) 
Ure2 [URE3] Regulation of nitrogen 
catabolism 
(Wickner 1994) 
Rnq1 [PIN+] So far unknown (Sondheimer and 
Lindquist 2000) 
HET-s* [Het-s] Heterokaryon 
incompatibility in the prion 
form; no function in the 
non-prion form 
(Coustou et al. 1997) 
Swi1 [SWI+] Chromatin remodeling (Du et al. 2008) 
Cyc8 [OCT+] Repression of 
transcription 
(Patel et al. 2009) 
Mot3 [MOT+] Regulation of transcription (Alberti et al. 2009) 
Sfp1 [ISP+] Transcription factor (Rogoza et al. 2010) 
Mod5 [MOD+] tRNA 
isopentenyltransferase 
(Suzuki et al. 2012) 
 
All listed proteins are capable of folding into amyloid fibrils (Wickner et al. 2015). * All prions 
except [Het-s] were found in Saccharomyces cerevisiae (S. cerevisiae). [Het-s] was 
discovered in Podospora anserina. 
 
Yeast prions are a very useful tool to analyze prion characteristics and their 
replication, as they share many mammalian prion properties. However, except for the 
oligopeptide repeats in PrP and the oligopeptide repeat region (OPR) of the 
Saccharomyces cerevisiae (S. cerevisiae) prion Sup35, PrP and the so far identified 
yeast prions share no sequence similarities. Unlike PrP, yeast prions are found in the 
cytosol and will therefore most likely differ from PrP in their replication. Yeast prions 
can be toxic to the host (McGlinchey et al. 2011), but in contrast to PrP, some have 
also been reported to have beneficial functions (Newby and Lindquist 2013). Two of 
the most extensively studied yeast prions are Ure2 and Sup35 (Ross, Minton, et al. 
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2005). The soluble form of Ure2 is a negative regulator of enzymes and transporters 
needed for the utilization of poor nitrogen sources (Wickner 1994). Sup35 functions 
as a translation termination factor. However, protein activity is lost upon conversion 
to the prion isoform, leading to a read-through of stop codons (Uptain and Lindquist 
2002). In a reporter assay, the prion isoform induced read-through of stop-codons is 
used to distinguish the soluble from the prion phenotype (Chernoff et al. 1995)     
(Fig. 3).  
 
 
 
 
 
Figure 3. Representation of Sup35 prions in yeast. A. Immunofluorescence staining of 
Sup35 fused to a GFP tag. Prion isoform (left), soluble isoform (right). B. Growth of yeast 
cells expressing the prion isoform (upper panel) of Sup35 and the soluble isoform (lower 
panel) on YPD medium with (left) or without (right) adenine. From Tuite and Cox (2003). 
 
In this color assay, the prion isoform of Sup35 reads through a premature stop codon 
in the ade1-14 allele, resulting in growth of white colonies on solid rich medium 
(YPD). In its soluble form, however, translation of adenine is prematurely halted, 
leading to the accumulation of metabolic byproducts and the formation of red 
colonies. The assay can be altered to select only strains carrying the prion isoform by 
growing yeast strains on medium deprived of adenine (Fig. 3B). 
Similar to the mammalian prion, yeast prions propagate by seeded polymerization 
(Fig. 2). The first step, conversion of the soluble isoform to the prion conformer, is a 
very rare event in yeast, with a frequency of ~ 10-7 (Lancaster et al. 2010). In analogy 
to PrP, prion fibrils are fragmented into smaller entities, offering numerous new 
conversion sites. In yeast, fragmentation depends on the heat-shock protein Hsp104 
in a concentration-dependent manner. Moderate amounts of Hsp104 are required to 
fragment assembled fibrils into smaller entities. Depletion of Hsp104 or excess 
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amounts on the other hand have been shown to cure the prion phenotype. This 
demonstrates that prion propagation in yeast depends on a well-balanced ratio of 
Sup35 and Hsp104 (Chernoff et al. 1995). In the final step, the generated propagons 
are distributed to the daughter cell or are naturally transmitted during mating (Uptain 
and Lindquist 2002). As yeast prions are not naturally transmitted to neighboring 
cells, their infectivity is assessed by cytoduction. Cytoduction is a process of 
cytoplasmic mixing without nuclei fusion, where it was shown that the prion 
phenotype is induced in a former non-prion bearing cell by mixing with cytoplasm of a 
prion-bearing cell (Aigle and Lacroute 1975, Wickner 1994). 
In line with the strain-phenomenon observed for mammalian prions (Bruce 1993), 
yeast prions can also adopt different conformations (Derkatch et al. 1996, 
Schlumpberger et al. 2001, Tanaka et al. 2004). In yeast, prion strains are often 
referred to as ''variants'', to distinguish them from the variety of laboratory yeast 
strains. For Sup35, prion variants are mostly distinguished by the loss of the protein's 
translation termination function and are classified as strong, moderate or weak 
(Derkatch et al. 1996). Strong Sup35 variants contain less soluble Sup35 compared 
to weak variants (Kochneva-Pervukhova et al. 2001). Strong Sup35 variants also 
show a higher efficiency in cell-free conversion assays (Uptain et al. 2001), where 
yeast lysates with no prion phenotype are converted to the prion isoform by mixing 
with yeast lysates showing the prion phenotype (Paushkin et al. 1997). In analogy to 
mammalian prion strains, yeast prion variants also show distinct physical properties 
in vitro (Chien and Weissman 2001), though upon further passaging their 
characteristics are lost in a cell-free environment (Uptain et al. 2001). Yeast prion 
variants also show differences in their amyloid core structures (Toyama et al. 2007). 
In yeast, prion properties are conferred by the prion domain (PrD). The PrD is a 
modular structure that retains its prion activity even when fused to other proteins (Li 
and Lindquist 2000, Baxa et al. 2002, MacLea and Ross 2011). Although the exact 
molecular structures that govern prion propensities have so far, not been entirely 
identified, extensive research over the last decade unraveled the fundamentals of 
PrDs (Li and Lindquist 2000, Alberti et al. 2009). Two major theories were put 
forward. In the first theory, the PrD is a large, disordered region in which many weak 
interactions drive aggregation (Toombs et al. 2012). In the second theory, 
aggregation is facilitated by a small, highly aggregation-prone domain that is 
embedded in a large, disordered region enriched in glutamine (Q) and asparagine 
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(N) residues (Sabate et al. 2015). Whether any of the two theories is ultimately 
correct, or different types of PrDs exist, has so far not been established. 
 
1.6 Structure of Sup35 
 
The prion phenomenon associated with Sup35 was first discovered in 1965 by Brian 
Cox, who described it as a non-chromosomal epigenetic element that does not 
segregate in a Mendelian fashion (Cox 1965). The full-length S. cerevisiae Sup35 
protein comprises 685 amino acids and consists of three domains: the aminoterminal 
N domain, the middle M domain and the carboxyterminal C domain (Fig. 4).  
 
 
 
 
 
Figure 4. Primary sequence of Sup35. Sup35 consists of three domains: The 
aminoterminal N domain, the middle M domain and the carboxyterminal C domain. The N 
domain is responsible for the prion activity and can be subdivided into a Q/N rich region 
(QNR), an oligopeptide repeat region (OPR) and a carboxyterminal N domain (CTN). The M 
domain is highly charged, influences the proteins solubility and stabilizes the amyloid fibril. 
The C domain encodes the translation termination function, but is dispensable for the prion 
characteristics of the protein. Numbers refer to amino acids. 
 
The C domain (aa 251-685) encodes the translation termination function of the 
protein, but is otherwise dispensable for its prion properties (Ter-Avanesyan et al. 
1993). The highly charged M domain influences the solubility of Sup35 and promotes 
mitotic stability of the prion state, possibly through interactions with Hsp104 (Liu et al. 
2002). The N domain is rich in glutamine and asparagine residues and contains the 
PrD (Ter-Avanesyan et al. 1993, Ter-Avanesyan et al. 1994, Derkatch et al. 1996). 
The N domain can be further subdivided into three regions: the especially glutamine- 
(32%) and asparagine- (24%) rich region (QNR, aa 1-39), the oligopeptide repeat 
region (OPR), consisting of five and a half imperfect oligopeptide repeats (R1 - R6, 
PQGGYQQ-YN, aa 40-97) and the carboxyterminal N domain (CTN), also rich in 
glutamine (19%) and asparagine (23%) residues (aa 98-123).  
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1.7 Defining the prion domain 
 
In recent years, extensive studies have been conducted to define and characterize 
PrDs. In general, most PrDs are described to be rich in glutamine and asparagine 
residues, contain only a few charged and hydrophobic amino acids and are located in 
an unstructured region (DePace et al. 1998, Alberti et al. 2009, Du 2011). Studies on 
Sup35 soon identified the N domain as the critical region for the appearance of the 
prion phenotype (Glover et al. 1997, King et al. 1997). Interestingly, in 2005, Ross 
and coworkers demonstrated that scrambling the PrD of Sup35 does not disrupt its 
prion propensity, arguing that it is the amino acid composition rather than the primary 
sequence that determines prion characteristics (Ross, Edskes, et al. 2005). These 
findings were later confirmed by Shewmaker and colleagues, who demonstrated that 
the molecular structure of normal and shuffled Sup35 prions most likely resembles an 
in-register β-sheet (Shewmaker et al. 2008, Shewmaker et al. 2009). However, even 
in shuffling studies, differences in prion characteristics, such as prion frequency and 
stability, were observed, indicating that although composition is of great importance, 
the primary sequence plays a major role, too.  
On the basis of primary sequence, numerous mutation and deletion studies were 
performed to define minimal regions within the N domain that are capable of inducing 
and propagating the prion phenotype. Many different yeast strains and prion variants 
were used, leading to minor variations in the experimental outcomes. Though 
differences in experimental setups complicate direct comparisons, some conclusion 
can be drawn. De novo aggregation of overexpressed NM (Sup35 that lacks its C 
domain) was found to depend on the QNR and the first two repeats of the OPR      
(aa 1-64) in two separate studies (Osherovich et al. 2004, Shkundina et al. 2006). 
Similar results were found by King and coworkers, who identified the first 61 amino 
acids to be required for de novo aggregation (King 2001). These results are in 
agreement with the finding that expression of Sup35 with mutations in the first 34 
amino acids of the QNR cure the prion phenotype (DePace et al. 1998). However, in 
studies conducted by Parham and colleagues, the QNR and the entire OPR            
(aa 1-97) were needed for aggregation (Parham et al. 2001). The same region       
(aa 1-97) was also discovered in the same study to be crucial for aggregate 
maintenance, data that agrees with findings from Osherovich (aa 1-97) and 
Shkundina (aa 1-83) (Parham et al. 2001, Osherovich et al. 2004, Shkundina et al. 
2006). Interestingly, in studies conducted by Chang and colleagues, only the QNR 
Introduction 
 11 
and the first repeat (aa 1-53) were required for prion infectivity (Chang et al. 2008). In 
accordance with the previous data, Toyama and coworkers could show that the first 
40 or, depending on the prion variant, the first 70 amino acids were protected from 
hydrogen-deuterium exchange experiments, arguing that those residues were part of 
the protected amyloid core region and thus crucial for aggregation (Toyama et al. 
2007). Interestingly, one single glycine to aspartic acid point mutation in the second 
repeat (aa 58) was shown to eliminate the prion phenotype, suggesting that the 
second repeat has a crucial function for aggregate fragmentation and consequently 
maintenance (Doel et al. 1994, Osherovich et al. 2004). Combined, these findings 
suggest that in vitro and in yeast, the QNR and the first two repeats are essential for 
de novo induction of prions, whereas the OPR is required for fragmentation and 
maintenance. 
 
1.8 Mammalian proteins with putative prion-like domains 
 
Based on compositional similarities of yeast PrDs, several prediction algorithms were 
generated to identify proteins with putative prion-like domains (PrLDs) (Alberti et al. 
2009, Espinosa Angarica et al. 2014, Lancaster et al. 2014). Surprisingly, these 
algorithms predict PrLDs in one percent of human protein-coding genes (King et al. 
2012). Amongst them are many RNA-binding proteins such as TDP-43 and FUS that 
form cytoplasmic inclusions in PMDs like amyotrophic lateral sclerosis (ALS) and 
frontotemporal lobar degeneration (FTLD). TDP-43 is involved in transcriptional 
regulation and splicing of RNA (Buratti and Baralle 2008, Buratti and Baralle 2010). 
TDP-43 is intrinsically aggregation-prone, but aggregation can be prevented upon 
deletion of its carboxyterminal PrLD (King et al. 2012). FUS functions in 
transcriptional regulation and RNA homeostasis (Bertolotti et al. 1996, Zinszner et al. 
1997, Kasyapa et al. 2005). Similar to TDP-43, aggregation of FUS is promoted by its 
aminoterminal PrLD (Couthouis et al. 2011, Sun et al. 2011). The high abundance of 
prion-like proteins in the human proteome suggests that prion-like behavior might be 
an evolutionary conserved feature. The aggregation-prone nature of many          
RNA-binding proteins is hypothesized to be involved in long-term memory similar to 
Aplysia Cytoplasmic Polyadenylation Element Binding protein (CPEB) (Si et al. 2003, 
Shorter and Lindquist 2005, Si et al. 2010). The PrLDs of RNA-binding proteins are 
also suggested to function in P-body and stress granules formation, as already 
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reported for TIA-1 (Gilks et al. 2004, King et al. 2012). However, whether mammalian 
proteins with PrLDs can truly fold into self-templating prions remains elusive. 
 
1.9 NM as a model system in mammalian cells 
 
The only known mammalian prion to date is the membrane-anchored PrP. Until 
recently, it was unclear if prion replication is possible in the mammalian cytosol. NM 
has no translation termination function and exhibits no sequence homology to 
mammalian proteins, making it a very suitable model to study cytosolic prion 
replication without a loss of function phenotype. The NM model system was 
established in our laboratory by transducing the mouse neuroblastoma cell line N2a 
with lentiviral particles coding for NM carboxyterminally fused to a hemagglutinin-tag 
(HA-tag). In this system, NM was shown to reside in its soluble state, with no 
detectable spontaneous aggregation (Krammer et al. 2009). Upon addition of in vitro 
fibrillized recombinant NM to the cell culture medium, aggregation of NM could be 
induced (Krammer et al. 2009). This is in analogy to experiments in yeast, where 
purified NM was seeded with NM aggregates derived from yeast cells carrying the 
prion isoform, and afterwards used to successfully induce the prion phenotype in 
yeast (King and Diaz-Avalos 2004). In N2a cells, induced aggregates stably 
propagate to daughter cells and act as infectious entities that horizontally transmit to 
bystander cells (Krammer et al. 2009, Hofmann et al. 2013). For successful 
propagation, high-molecular weight conformers must be fragmented into smaller 
entities. In yeast, Hsp104 was shown to be one of the major components responsible 
for fragmentation and consequently, maintenance of the prion phenotype (Chernoff et 
al. 1995). Intriguingly, to date no mammalian homologue of Hsp104 has been 
identified, suggesting that fragmentation is facilitated by a different, and so far 
unknown machinery in mammalian cells. Limiting dilution cloning of cells stably 
propagating NM aggregates revealed morphologically and biochemically different 
aggregate types that were stably propagated, reminiscent of prion variants in yeast 
(Krammer et al. 2009). Interestingly, cell extracts from NM-HA aggregate bearing cell 
clones could induce the prion phenotype in yeast (Krammer et al. 2009). Though 
induction was less efficient compared to inductions with extracts derived from yeast 
carrying the prion isoform, the results demonstrated that NM aggregates derived from 
mammalian cells function as true prions (Tanaka et al. 2004, Brachmann et al. 2005, 
Krammer et al. 2009). Combined, these results illustrate that NM prions behave as 
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infectious entities in mammalian cells and fulfill the entire life cycle of cytosolic prions. 
Thus, the NM system provided proof-of-principle that cytosolic prion replication is 
possible in mammalian cells (Fig. 5). 
 
 
 
 
Figure 5. Scheme depicting the cytosolic NM prion life cycle. (a) The prion precursor 
protein resides in its soluble state, (b) aggregation is induced upon addition of exogenous 
NM fibrils, (c) aggregates are fragmented and propagons inherited by daughter cells,           
(d) propagons invade neighboring cells and induce a self-perpetuating prion state of the prion 
precursor protein. 
 
1.10 Objective 
 
Extensive research has been conducted to identify and further characterize domains 
that govern prion properties, so-called prion or prion-like domains. Prion domains are 
often enriched in glutamine and asparagine, lack charged amino acids and are 
usually located in unstructured regions. Early on the N domain was identified as the 
prion domain of Sup35 and later on further subcategorized into regions crucial for   
de novo aggregation and maintenance of the prion phenotype in yeast. Based on 
these and other experiments performed in vitro and in yeast, several algorithms have 
been developed to detect so far unknown prion-like proteins in lower eukaryotes as 
well as in mammals. Interestingly, algorithms have predicted that one percent of the 
human proteome contain prion-like domains. Yet, whether domains that share 
compositional similarity to yeast prion domains also govern prion-like properties in 
mammalian cells has not been analyzed so far. The aim of this study was to identify 
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essential elements required for the individual steps of cytosolic prion replication in 
mammalian cells using the already established NM N2a cell model. In this study, NM 
proteins with deletions or a point mutation in the N domain of Sup35 should be stably 
expressed in mouse neuroblastoma cell line N2a. The individual cell lines should be 
screened for events of spontaneous aggregation by high-throughput confocal 
microscopy to detect rare events of prion induction. Aggregation of the ectopically 
expressed NM mutants should be induced by either exogenous recombinant NM 
fibrils or endogenous NM prions and should be analyzed for differences in the 
induction efficiencies compared to the full-length protein. Following successful 
aggregate induction, the NM mutant cell lines should be monitored for aggregate 
maintenance. To complete the prion replication cycle, the infectious properties of NM 
mutants should be investigated by coculture experiments of cells with and without 
aggregates. Combined, this research should present a more detailed insight into 
sequence requirements for cytosolic prion replication in the mammalian context. This 
knowledge will help to optimize prediction algorithms for the search of so far 
unknown prion-like proteins in mammals. 
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2. Materials and methods 
 
2.1 Biological safety 
 
Genetic engineering and work with genetically modified organisms was conducted 
under biosafety containment level 2 according to the German Gentechnikgesetz 
(August 31st, 2015). All contaminated materials and solutions were collected, 
decontaminated and disposed following the official rules.  
 
2.2 Chemicals 
 
All chemicals were purchased from Carl Roth (Karlsruhe, Germany) or Sigma-Aldrich 
(Steinheim, Germany), unless stated otherwise. 
 
2.3 Molecular biological methods 
 
2.3.1 Polymerase chain reaction (PCR) 
 
Kapa Hifi PCR kit Kapa Biosytems, Cape Town, South Africa 
 
For amplification or modification of DNA constructs, Kapa Hifi PCR kit was used with 
a specific primer pair according to the manufacturer’s instructions (Table 2). 
 
Table 2: Oligodeoxynucleotides 
 
Name Sequence (5’ - 3’) 
NM-HA_linker GTC GAC TTA AGC GTA ATC TGG TAC GTC GTA TGG 
GTA GAA TTC AAC TTC GTC ATC CAC 
TS9 TAA AGG ATC CGT CGC CAC CAT GTC CGA TTC AAA 
CCA AGG 
TS2 ATA TTG AAT TCA ACT TCG TCA TCC ACT TCT TC 
N-domain_EcoRI_addition GAA TTC ACC TTG AGA CTG TGG TT 
NM_del_1-39_fwd GGA TCC GTC GCC ACC ATG CAA CCT GCA GGT GG 
NM_del_39-123_fwd TAC AAT GCT CAA ATG TCT TTG AAC GAC TTT C 
NM_del_39-123_rev GTC GTT CAA AGA CAT TTG AGC ATT GTA AGC 
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NM_del_75-123_fwd CAA CAG TAT AAT ATG TCT TTG AAC GAC TTT C 
NM_del_75-123_rev GTC GTT CAA AGA CAT ATT ATA CTG TTG CTG G 
NM_del_98-123_fwd CCA CAA GGT GGC ATG TCT TTG AAC GAC TTT C 
NM_del_98-123_rev GTC GTT CAA AGA CAT GCC ACC TTG TGG ATT G 
 
2.3.2 Enzymatic digestion of plasmid DNA 
 
Restriction enzymes and buffers New England Biolabs, Ipswich, USA 
 
For each reaction, approximately 1 µg plasmid DNA was digested. The appropriate 
buffer was chosen according to the restriction enzymes used for individual 
experiments. The reagents were mixed according to the manufacturer’s instructions 
and incubated for 3 - 4 h at 37 °C. 
 
2.3.3 Enzymatic ligation of DNA 
 
T4 DNA ligase and buffer New England Biolabs, Ipswich, USA 
 
Vector DNA and insert DNA were ligated at a molar ratio of 1:3 with a combined 
amount of approximately 100 ng. DNA, ligase and buffer were mixed according to the 
manufacturer’s instructions and incubated for 1 h at room temperature (RT) or 
overnight (O/N) at 16 °C. 
 
2.3.4 Agarose gel electrophoresis 
 
1x TAE buffer 40 mM Tris/HCl, pH 7.6 
 20 mM Acetic acid 
 1 mM EDTA 
 in H2Obidest 
 
Agarose Biozym, Hessisch Oldendorf, Germany 
6x DNA Loading buffer Peqlab, Erlangen, Germany 
1 kb DNA ladder Carl Roth, Karlsruhe, Germany 
GelRED Biotium, Hayward, USA 
 
To prepare agarose gels, 1 - 3 % agarose was melted in TAE buffer. The appropriate 
amount of GelRED (1:10000) was added and the agarose solution was poured into 
an electrophoresis chamber (Peqlab, Erlangen, Germany) equipped with a comb. 
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After the gel was solidified, the chamber was filled with TAE buffer and the comb 
removed. DNA samples supplemented with DNA loading buffer were loaded into the 
wells along with 3 µl of DNA marker as a reference for the size of the DNA 
fragments. The gel was run at 80 - 100 V for 60 - 90 min, depending on the agarose 
concentration and the size of the gel. Images of the gel were taken with a gel 
documentation system (Stella, Raytest, Straubenhardt, Germany) using UV 
illumination and a digitally controlled video camera.  
 
2.3.5 DNA extraction from agarose gels 
 
Gel Extraction Kit Qiagen, Venlo, Netherlands 
 
DNA was visualized with the UV transilluminator (Biostep, Burkhardtsdorf, Germany). 
The appropriate DNA band was cut out and DNA was extracted from residual 
agarose using the Gel Extraction Kit according to the manufacturer’s instructions.  
 
2.3.6 Generation of chemically competent E.coli 
 
LB medium 2 % LB Broth-agar 
 in H2Obidest 
 
To generate chemically competent bacteria, 2 ml of LB medium were inoculated with 
one colony of DH5α or BL21 Escherichia coli (E.coli) and incubated in a shaker at 
220 rpm O/N at 37 °C (LT-X Lab-Therm, Kuhner Shaker, Aachen, Germany). The 
next day, 100 ml of LB medium were inoculated with 500 µl of the O/N culture and 
shaken at 220 rpm and 37 °C until an OD600 of 0.3 was reached (LT-X Lab-Therm, 
Kuhner Shaker, Aachen, Germany). The bacteria were cooled on ice for 10 min and 
afterwards centrifuged at 1500 x g for 10 min at 4 °C (Heraeus Multifuge X3R, 
Thermo Scientific, Waltham, USA). The supernatant was discarded and the bacteria 
were carefully resuspended in 10 ml 0.1 M MgCl2. As the bacteria are sensitive after 
MgCl2 and the subsequent CaCl2 treatment, all following steps were conducted on 
ice. The bacteria were centrifuged at 1500 x g for 10 min at 4 °C and the supernatant 
was discarded. The bacteria pellet was resuspended in 20 ml 0.1 M CaCl2 and 
incubated for 20 min on ice. Centrifugation was repeated and the pellet resuspended 
in 1 ml 0.1 M CaCl2 supplemented with 15 % glycerol. Cells were snap frozen in     
50 µl aliquots and stored at -80 °C until further use. 
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2.3.7 Transformation of chemically competent E.coli 
 
Depending on the experiment, either DH5α or BL21 E.coli were thawed and 
incubated with 10 - 50 ng plasmid DNA or half of the ligation mixture for 30 min on 
ice (Table 3). Afterwards, the bacteria were exposed to heat shock for 42 sec at      
42 °C and subsequently cooled for 1 - 2 min on ice. 1 ml LB medium was carefully 
added and the bacteria were shaken at 300 rpm for 30 - 60 min at 37 °C 
(Thermomixer Compact, Eppendorf, Hamburg, Germany). To remove excess 
medium, the bacteria were spun down at 514 x g for 3 min at RT (Eppendorf 
Centrifuge 5417R, Hamburg, Germany). Most of the supernatant was discarded and 
the bacteria pellet was resuspended in the remaining medium. The bacteria were 
plated onto LB agar plates supplemented with either 100 µg/ml Kanamycin or 
Ampicillin, depending on the transformed plasmid. The plates were incubated O/N at 
37 °C and could afterwards be stored at 4 °C. 
 
Table 3: Plasmids  
 
Construct Tag Vector Backbone 
NM HA pJ602 
NM ∆ 1-39 HA pJ602 
NM ∆ 39-123 HA pJ602 
NM ∆ 75-123 HA pJ602 
NM ∆ 98-123 HA pJ602 
NM G58D HA pJ602 
NM ∆ 39-57 HA pJ602 (DNA 2.0, Menlo Park, USA) 
NM ∆ 39-74 HA pJ602 (DNA 2.0, Menlo Park, USA) 
NM ∆ 75-97 HA pJ602 (DNA 2.0, Menlo Park, USA) 
NM HA pRRL.sin.PPT.CMV.Wpre                       
(Follenzi and Naldini 2002) 
NM ∆ 1-39 HA pRRL.sin.PPT.CMV.Wpre 
NM ∆ 39-123 HA pRRL.sin.PPT.CMV.Wpre 
NM ∆ 75-123 HA pRRL.sin.PPT.CMV.Wpre 
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NM ∆ 98-123 HA pRRL.sin.PPT.CMV.Wpre 
NM G58D HA pRRL.sin.PPT.CMV.Wpre 
NM ∆ 39-57 HA pRRL.sin.PPT.CMV.Wpre 
NM ∆ 39-74 HA pRRL.sin.PPT.CMV.Wpre 
NM ∆ 75-97 HA pRRL.sin.PPT.CMV.Wpre 
 HA pRRL.sin.PPT.CMV.Wpre 
 GFP pRRL.sin.PPT.CMV.Wpre 
NM ∆ 39-123  pMK (Geneart, Waltham, USA) 
N  pMK (Geneart, Waltham, USA) 
N HA pJ602 
N Myc pJ602 
NM ∆ 138-250 HA pJ602 (DNA 2.0, Menlo Park, USA) 
NM ∆ 138-250 Myc pJ602 
M Myc pcDNA3.1 (Thermo Scientific, Waltham, USA) 
  pMDl.g/pRRE (Follenzi and Naldini 2002) 
  pMD2.VSVG (Follenzi and Naldini 2002) 
  pRSV-Rev (Follenzi and Naldini 2002) 
NM  pNOTAG (Jens Tyedmers, University 
Heidelberg) 
 
2.3.8 Cultivation of bacteria and preparation of plasmid DNA 
 
Plasmid Mini Kit Qiagen, Venlo, Netherlands 
Plasmid Maxi Kit Qiagen, Venlo, Netherlands 
 
One bacteria colony cultivated on LB agar plates was used to inoculate either 5 ml 
(mini culture) or 200 ml (maxi culture) LB medium supplemented with 100 µg/ml of 
the appropriate antibiotic. The culture was grown at 180 rpm O/N at 37 °C             
(LT-X Lab-Therm, Kuhner Shaker, Aachen, Germany). The following day, plasmid 
DNA was isolated from the cultures using either the Plasmid Mini or Maxi Kit 
according to the manufacturer’s instructions. Plasmid DNA was resuspended in 50 µl 
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(Mini Kit) or 300 µl (Maxi Kit) of the supplied buffer and DNA concentration was 
determined using the Nanodrop (Thermo Scientific, Waltham, USA). Plasmid DNA 
was stored at -20 °C. 
 
2.3.9 DNA sequence analysis 
 
DNA sequencing was conducted using the GATC Biotech Sanger sequencing 
service (Konstanz, Germany). Sequence information was analyzed using the Serial 
Cloner 2.6.1 Software. 
 
2.4 Cell culture 
 
Cell culture was performed under sterile conditions in a sterile hood with sterile 
medium, glass and plastic ware. Cells were cultured in a cell incubator (HERAcell 
240i, Thermo Scientific, Waltham, USA) at 37 °C in a humidified 5 % CO2 
atmosphere. 
 
2.4.1 Thawing of cells 
 
N2a culture medium  Dulbecco’s Modified Eagle Medium (DMEM) 
 + GlutaMAX (Gibco, Waltham, USA) 
10 % Fetal Calf Serum (FCS) (Biochrom, 
Kenilworth, USA) 
 
Hek293T/17 culture medium Iscove’s Modified Dulbecco’s Medium (IMDM) 
10 % FCS (Biochrom, Kenilworth, USA) 
1 % Penicillin/Streptomycin (Gibco, Waltham, 
USA)  
3.024 g/L Sodium bicarbonate 
 
Cells frozen in liquid nitrogen were thawed, resuspended in culture medium and 
centrifuged at 314 x g for 5 min at RT (Heraeus Multifuge X3R, Thermo Scientific, 
Waltham, USA) (Table 4). The supernatant was discarded and the cell pellet was 
resuspended in culture medium. Cells were plated on cell culture flasks or on dishes 
and cultured as described (2.4.2). 
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Table 4: Cell lines  
 
Cell line Property Reference 
N2a Murine neuroblastoma cell 
line 
ATCC CCL 131;   Butler et 
al. (1988) 
N2a NM-HA N2a cells expressing NM-HA Generated in this study 
N2a NM-HAagg                     
clone 5A 
N2a cell clone producing      
NM-HA aggregates 
Generated in this study 
N2a NM-HAagg                     
clone 7A 
N2a cell clone producing       
NM-HA aggregates 
Generated in this study 
N2a NM-HAagg                    
clone 10A 
N2a cell clone producing       
NM-HA aggregates 
Generated in this study 
N2a NM-HAagg                     
clone 5B 
N2a cell clone producing      
NM-HA aggregates 
Generated in this study 
N2a NM-HA ∆ 1-39 N2a cells expressing            
NM-HA ∆ 1-39 
Generated in this study 
N2a NM-HAagg ∆ 1-39         
clone 5A 
N2a cell clone producing      
NM-HA ∆ 1-39 aggregates 
Generated in this study 
N2a NM-HAagg ∆ 1-39         
clone 1B 
N2a cell clone producing      
NM-HA ∆ 1-39 aggregates 
Generated in this study 
N2a NM-HAagg ∆ 1-39         
clone 2B 
N2a cell clone producing      
NM-HA ∆ 1-39 aggregates 
Generated in this study 
N2a NM-HAagg ∆ 1-39          
clone 5D 
N2a cell clone producing      
NM-HA ∆ 1-39 aggregates 
Generated in this study 
N2a NM-HA ∆ 39-123 N2a cells expressing            
NM-HA ∆ 39-123 
Generated in this study 
N2a NM-HA ∆ 75-123 N2a cells expressing            
NM-HA ∆ 75-123 
Generated in this study 
N2a NM-HAagg ∆ 75-123      
clone 8H-13 
N2a cell clone producing      
NM-HA ∆ 75-123 aggregates 
Generated in this study 
N2a NM-HAagg ∆ 75-123     
clone 8H-23 
N2a cell clone producing      
NM-HA ∆ 75-123 aggregates 
Generated in this study 
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N2a NM-HAagg ∆ 75-123     
clone 64H-3 
N2a cell clone producing      
NM-HA ∆ 75-123 aggregates 
Generated in this study 
N2a NM-HAagg ∆ 75-123     
clone 64H-20 
N2a cell clone producing      
NM-HA ∆ 75-123 aggregates 
Generated in this study 
N2a NM-HA ∆ 98-123 N2a cells expressing            
NM-HA ∆ 98-123 
Generated in this study 
N2a NM-HA G58D N2a cells expressing            
NM-HA G58D 
Generated in this study 
N2a NM-HA ∆ 39-57 N2a cells expressing             
NM-HA ∆ 39-57 
Generated in this study 
N2a NM-HA ∆ 39-74 N2a cells expressing            
NM-HA ∆ 39-74 
Generated in this study 
N2a NM-HA ∆ 75-97 N2a cells expressing            
NM-HA ∆ 75-97 
Generated in this study 
N2a NM-GFP N2a cells expressing NM-
GFP 
Hofmann et al. (2013) 
N2a NM-GFPagg                  
clone 2CG11 
N2a cell clone producing      
NM-GFP aggregates 
Hofmann et al. (2013) 
N2a-GFP ∆ 1-39 N2a cells expressing            
NM-GFP ∆ 1-39 
Peer-Hendrik Kuhn, Stefan 
Lichtenthaler, Munich 
N2a NM-GFP ∆ 75-123 N2a cells expressing             
NM-GFP ∆ 75-123 
Peer-Hendrik Kuhn, Stefan 
Lichtenthaler, Munich 
Hek293T/17 Human embryonic kidney 
cells, expressing simian virus 
40 large T antigen, clone 17 
ATCC CRL-11268, Graham 
et al. (1977) 
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2.4.2 Culturing of cells 
 
PBS   Gibco, Waltham, USA 
Trypsin-EDTA, 0.05 % Gibco, Waltham, USA 
 
Cells were grown in cell culture flasks or dishes containing culture medium and 
passaged every 3 - 4 days. For passaging, the medium was aspirated, the cells were 
washed with PBS and incubated in Trypsin-EDTA for 5 min. Trypsin was inactivated 
by adding at least one volume of cell culture medium. After resuspension, the cells 
were centrifuged at 314 x g for 5 min at RT (Heraeus Multifuge X3R, Thermo 
Scientific, Waltham, USA) and the supernatant was discarded. The pellet was 
resuspended in approximately 5 ml of cell culture medium and, if needed, the cell 
number was determined using the automated cell counter (TC 20, BioRAD, Hercules, 
USA). The cell suspension was plated on fresh cell culture flasks, dishes or multi-well 
plates and cells were cultivated in a cell incubator (2.4). 
 
2.4.3 Cryoconservation of cells 
 
For cryoconservation, cells were detached as described (2.4.2) and pelleted at       
314 x g for 5 min at 4 °C (Heraeus Multifuge X3R, Thermo Scientific, Waltham, USA). 
Cell pellets were resuspended in FCS + 10 % DMSO and transferred into cryogenic 
vials. Vials were frozen O/N at -80 °C and transferred into liquid nitrogen the 
following day. Cells were kept in liquid nitrogen for long-term storage. 
 
2.4.4 Transient transfection of cells 
 
Efectene Transfection Reagent Qiagen, Venlo, Netherlands 
Kit 
Lipofectamine 2000 Transfection Thermo Scientific, Waltham, USA 
Reagent 
 
For transient transfection of cells, Effectene Transfection Reagent Kit or 
Lipofectamine 2000 Transfection Reagent were used according to the manufacturer’s 
instructions. 
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2.4.5 Production of lentiviral particles 
 
0.1 % TE buffer 1 mM Tris/HCl, pH 8.0 
0.1 mM EDTA, pH 8.0 
in H2Obidest 
 
2x HBSS 281 mM NaCl 
 100 mM HEPES 
 1.5 mM Na2HPO4, pH 7.12 
 in H2Obidest 
 
5x Polyethylene glycol 25 mM Polyethylene glycol 
 0.2 M NaCl 
 2 mM Tris/HCl, pH 7.5 
 in H2Obidest 
 
During lentiviral production and transduction of cells with lentiviral particles, two sets 
of gloves, arm protection, safety goggles and a surgical mask were worn at all times. 
To immediately decontaminate liquid waste, liquid waste was collected in 1 l glass 
bottles already prepared with 500 ml 20 % SDS (10 % SDS final concentration) and 
afterwards autoclaved following the official guidelines. During centrifugation steps, 
centrifugation buckets were always sealed with the appropriate lids. 
 
Table 5: Lentiviral plasmids and their function 
 
Plasmid 
Amount of DNA (µg) for 
transfection of 7x 15 cm 
dishes 
Function 
pMDl.g/pRRE 112 Packaging plasmid 
pRSV-Rev 44 Rev encoding plasmid 
pMD2.VSVG 63 Envelop plasmid 
pRRL.sin.PPT.CMV.NM-HA 
mutant.Wpre 
175 Expression plasmid 
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Lentiviral particles were produced using the method of Follenzi and Naldini (2002). 
To generate viral particles, approximately 7.5 x 106 Hek293T/17 cells were plated on   
7x 15 cm dishes and grown in 25 ml Hek293T/17 medium (~ 40 % confluency). Cells 
were grown for 5 - 7 h and afterwards transfected using the calcium phosphate 
precipitation method. For transfection, 7645 µl 0.1 % TE buffer, 875 µl 2.5 M CaCl2 
and the lentiviral plasmids (Table 5) were mixed in a 50 ml conical tube. The mixture 
was applied drop wise to 7875 µl vigorously vortexed 2x HBSS in a 50 ml conical 
tube using a serological pipette to produce DNA – calcium - phosphate precipitates. 
The transfection solution was evenly distributed on the culture dishes in a drop wise 
manner. 12 - 16 h post transfection, the medium was replaced with fresh culture 
medium. The day after, the medium was collected and the cells were cultured for 
another 24 h in fresh medium. To remove residual cells and cell debris, the collected 
medium was centrifuged at 690 x g for 5 min at 4 °C (Heraeus Multifuge X3R, 
Thermo Scientific, Waltham, USA) and the supernatant was stored at 4 °C. The 
following day, the medium was collected again and centrifuged as described before. 
At this point cells were discarded. The combined supernatant was filtered through a 
0.22 µm Corning bottle-top vacuum filter, mixed with 5x PEG (1x PEG final 
concentration) and incubated O/N at 4 °C in aliquots in 50 ml conical tubes. The next 
day, the precipitated viral particles were centrifuged at 1500 x g for 30 min at 4 °C 
and the supernatant was discarded. The pellets were carefully combined and again 
centrifuged at 1500 x g for 5 min at 4 °C. The supernatant was discarded and the 
lentiviral particles were carefully resuspended in 800 - 1000 µl PBS, depending on 
the pellet size. Aliquots were stored at -80 °C. 
 
2.4.6 Lentiviral transduction of mammalian cells 
 
Transduction medium  5 % FCS (Biochrom, Kenilworth, USA) 
 8 µg/ml Polybrene (Merck Millipore, Billerica, 
USA) 
 in DMEM (Gibco, Waltham, USA) 
 
Prior to transduction, 8 x 104 cells were plated on one well of a 24 - well plate and 
cultured O/N. On the day of transduction, culture medium was replaced with 
transduction medium and the appropriate amount of lentiviral particles was added to 
the cells. The well plate containing the cells and viral particles was centrifuged at  
800 x g for 10 min at RT (Heraeus Multifuge X3R, Thermo Scientific, Waltham, USA) 
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and afterwards cultured for 24 h. The next day, the medium was exchanged with 
fresh culture medium and the cells were expanded. Aliquots of generated stable cell 
lines were frozen in liquid nitrogen to be used for future experiments as described 
(2.4.3). 
 
2.4.7 Immunofluorescence staining and confocal microscopy analysis of N2a 
cells 
 
High Precision Microscope Marienfeld Superior, Lauda-Königshofen, 
Cover Glass, No 1.5H Germany 
Microplate, 96 - well, µ-clear, Greiner Bio-One, Kremsmünster, Austria 
F-Bottom, black 
Hoechst 33342  Molecular Probes, Eugene, USA 
HCS CellMask Blue Stain  Molecular Probes, Eugene, USA 
Aqua Polymount Polysciences, Warrington, USA 
Superfrost Plus Microscopic  Thermo Scientific, Waltham, USA 
Slides 
 
For immunofluorescence staining, N2a cells were grown on coverslips or 96 - well 
plates coated with Poly-L-lysine. To this end, coverslips or 96 - well plates were 
coated with Poly-L-lysine in PBS (1:100) O/N at RT. The following day Poly-L-lysine 
was discarded and the coverslips or 96 - well plates were washed three times with 
PBS before the cells were plated. Cells were grown for at least 24 h and treated 
according to the individual experiments. Cells were fixed with 4 % paraformaldehyde 
for 10 min (coverslips) or 15 min (96 - well plates) at RT. Cells were rinsed three 
times with PBS and afterwards permeabilized for 5 min (0.1 % Triton X-100, 
coverslips) or 10 min (0.5 % Triton X-100, 96 - well plates) at RT. After three washing 
steps, the cells were blocked with 2 % goat serum in PBS for 1 h at RT. NM was 
detected by staining with the indicated primary antibody diluted in 2 % blocking 
solution O/N at 4 °C (Table 6). Unbound antibody was removed by washing the cells 
three times for 5 min in PBS. Subsequently, the cells were incubated with the 
appropriate fluorophore - coupled secondary antibody in blocking solution (1:500) for 
1 h at RT (Table 7). After three washing steps with PBS for 5 min, nuclei were 
stained with Hoechst 33342 in PBS (1:10000) for 5 min at RT. For automated 
confocal microscopy, cytoplasm was visualized using HCS CellMask Blue Stain 
(1:5000) in PBS for 10 min at RT. The cells were rinsed six times with PBS and one 
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time with H2Obidest before they were mounted on microscopic slides. Microscopic 
slides were stored at 4 °C. Cells stained on 96 - well plates were kept in PBS at 4 °C. 
Confocal microscopy was performed using the LSM 700 (Zeiss, Jena, Germany) or 
the upright LSM 700 (Zeiss, Jena, Germany). For high-throughput analysis, cells 
were imaged with an automatic confocal microscope (Cell Voyager 6000, Yokogawa, 
Tokyo, Japan). Image analysis was performed using the Cell Profiler cell image 
analysis software. 
 
Table 6: Primary antibodies 
 
Antibody Origin Specificity Dilution Reference 
Anti–hemagglutinin 
(HA) F7  
Mouse 
monoclonal 
Epitope of 
hemagglutinin 
(YPYDVPDYA) 
IF            
1:200 
Santa Cruz 
Biotechnology, 
Santa Cruz, USA 
Anti-hemagglutinin 
(HA) (3F10) 
Rat 
monoclonal 
Epitope of 
hemagglutinin 
(YPYDVPDYA) 
WB        
1:1000 
Roche Diagnostics, 
Basel, Switzerland 
Anti-hemagglutinin 
(HA) Alexa 647 
Mouse 
monoclonal 
Epitope of 
hemagglutinin 
(YPYDVPDYA) 
IF            
1:200 
Biozol, Eching, 
Germany 
Anti–actin (C4) Mouse 
monoclonal 
Chicken gizzard 
actin, all six known 
vertebrate isoactins 
WB        
1:5000 
MP Biomedicals, 
Eschwede, 
Germany 
Anti–NM (4A5) 
(hybridoma 
supernatant) 
Rat 
monoclonal  
M domain of Sup35  
(aa 229-247) 
WB            
1:10 
Provided by           
Dr. Kremmer, 
Helmholtz Zentrum, 
Munich, Germany 
Anti–Myc-tag Rabbit 
polyclonal 
Epitope of c-myc 
(EQKLISEEDL) 
IF            
1:500 
Abcam, Cambridge, 
UK 
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Table 7: Secondary antibodies 
 
Antibody Origin Specificity Dilution Reference 
Horseradish 
peroxidase (HRP) 
conj. anti-rat IgG 
Goat Rat IgG 1:10000 Dianova, Hamburg, 
Germany 
Horseradish 
peroxidase (HRP) 
conj. anti-mouse IgG 
Goat Mouse IgG 1:10000 Dianova, Hamburg, 
Germany 
Alexa Fluor 488-
conj. anti-mouse 
Goat Mouse IgG 1:500 Life Technologies, 
Darmstadt, 
Germany 
Alexa Fluor 594-
conj. anti-mouse 
Goat Mouse IgG 1:500 Life Technologies, 
Darmstadt, 
Germany 
Alexa Fluor 488-
conj. anti-rabbit 
Goat Rabbit IgG 1:500 Life Technologies, 
Darmstadt, 
Germany 
Alexa Fluor 568-
conj. anti-rabbit 
Goat Rabbit IgG 1:500 Life Technologies, 
Darmstadt, 
Germany 
 
2.4.8 Aggregate induction by recombinant NM fibrils 
 
For aggregate induction, recombinant NM protein was prepared as described (2.5.8). 
To generate fibrils, the NM protein was thawed and rotated head-over-tail at 50 rpm 
for 24 h at 4 °C (LD-76, Labinco, DG Breda, Netherlands) at a concentration of        
10 - 100 µM (monomer concentration), depending on the experiment. To dissociate 
fibrils into smaller fragments more likely to enter the cell, NM fibrils were sonicated 
for 3 min (5 sec on, 1 sec off) in an ice-cold water bath, with the amplitude set to     
10 % (Sonicator Sonoplus, Bandelin, Berlin, Germany). Fibrils were added to the 
cells (1 or 10 µM final concentration, monomer concentration) seeded on 24 - well 
plates the day before. After 24 h, the medium was exchanged and the cells were 
further passaged or directly analyzed. 
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2.4.9 Aggregate maintenance analysis 
 
To analyze the maintenance of NM aggregates over several passages, N2a          
full-length NM-HA and NM-HA mutant cells at passage three were seeded on          
24 - well plates and grown O/N. Recombinant NM fibrils were generated as described 
(2.4.8, 2.5.8) and added to the cells for 24 h (10 µM, monomer concentration). After 
fibril induction, cells were expanded to T25 - flasks and grown until passage nine 
post induction. During the cultivation at passage one, three, six and nine post 
induction, cells were also seeded on Poly-L-lysine coated 96 - well plates for 
immunofluorescence analysis (2.4.7).  
 
2.4.10 Time-lapse analysis 
 
4 - well chamber slides Nunc, Thermo Scientific, Waltham, USA 
 
N2a cells expressing full-length and mutant NM-GFP were seeded on 24 - well plates 
24 h prior to induction with 10 µM recombinant NM fibrils (monomer concentration) 
(2.4.8). Cells were grown for another two passages and afterwards plated on 4 - well 
chamber slides. After 24 h, time-lapse images were taken over a period of 15 h using 
a wide-field fluorescence microscope (Zeiss, Jena, Germany) at 37 °C and 5 % CO2. 
 
2.4.11 Limiting dilution cloning 
 
For limiting dilution cloning, cells were detached and the cell number was determined 
as described (2.4.2). The cells were diluted to a final concentration of 10 cells/ml and 
seeded (100 µl/well) on 96 - well plates. Cells were cultured for approximately         
10 days and afterwards, single cell clones were selected. Single cell clones were 
expanded to 24 - and subsequently 6 - well plates. To detect NM aggregate bearing 
cell clones, clones were seeded on 96 - well plates and analyzed by 
immunofluorescence staining (2.4.7). Each cell clone was frozen in liquid nitrogen as 
described (2.4.3). 
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2.4.12 Generation of full-length and mutant N2a NM-HAagg cell clones 
 
Effectene Transfection Reagent Qiagen, Venlo, Netherlands 
Kit 
 
Aggregate induction was performed as previously described (2.4.8). To enhance the 
fibril induction rate, fibrils were mixed with the appropriate amount of Effectene 
transfection reagents used for transfection in 24 - well plates (see manufacturer's 
instructions), prior to addition to N2a cells. After three passages, the percentage of 
aggregate bearing cells in the N2a NM-HA expressing bulk populations was 
determined (2.4.7). Aggregate bearing single cell clones were afterwards generated 
by limiting dilution cloning (2.4.11). For NM mutant NM-HAagg ∆ 75-123, a second 
limiting dilution cloning step was necessary as the first round resulted in mitotically 
instable cell clones. Cell clones were frozen in liquid nitrogen for future experiments. 
 
2.4.13 Coculture analysis 
 
N2a NM-HAagg donor clones were cocultured with N2a NM-GFPsol recipient cells 
(ratio 1.5:1) on Poly-L-lysine coated coverslips (1.25 x 105 total cells) or 96 - well 
plates (2.5 x 104 total cells). After 42 h, cells were fixed and stained as described 
(2.4.7). Confocal images were taken with the LSM 700 (Zeiss, Jena, Germany), the 
upright LSM 700 (Zeiss, Jena, Germany) or the automatic confocal microscope (Cell 
Voyager 6000, Yokogawa, Tokyo, Japan), respectively. 
 
2.5 Protein biochemical methods 
 
2.5.1 Preparation of protein lysates from mammalian cells 
 
Lysis buffer 150 mM NaCl 
 50 mM Tris/HCl, pH 7.5 
 0.5 % NP-40 
 in H2Obidest 
 Protease inhibitor (complete, EDTA free, Roche 
Diagnostics, Basel, Switzerland) 
 
Cells were detached from cell culture dishes (2.4.2) and centrifuged at 314 x g for     
5 min at 4 °C (Heraeus Multifuge X3R, Thermo Scientific, Waltham, USA). Cell 
pellets were washed in ice-cold PBS and either lysed directly or stored at -20 °C until 
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further use. Cell pellets were resuspended in the appropriate amount of lysis buffer 
freshly supplemented with protease inhibitor (1 x T75 – flasks: 1 ml; 1 x 6 – well:   
100 µl; 1x 24 – well: 50 µl) and lysed for 30 min on ice. Cell debris was spun down at 
514 x g for 3 min at 4 °C (Eppendorf Centrifuge 5417R, Hamburg, Germany) and the 
supernatant was transferred into a fresh tube. Protein lysates were either used 
directly or stored at -20 °C. 
 
2.5.2 Bradford protein assay  
 
Quick Start Bradford Assay BioRAD, Hercules, USA 
Quick Start Bovine Serum Albumin BioRAD, Hercules, USA 
Standard Set 
 
To determine the protein concentration of cell lysates, the Bradford protein assay 
was used. A clear 96 - well plate was prepared with 5 µl of a 1:10 dilution of the 
protein lysate in H2Obidest in duplicates, a BSA standard dilution series ranging from 
62.5 - 2000 µg/ml and a H2O blank control. The chemical reaction was started by 
addition of 250 µl Bradford reagent, resulting in a protein concentration dependent 
color change in each sample. After 5 min incubation, the absorbance was measured 
at 595 nm with the plate reader (FLUOstar Omega, BMG Labtech, Offenburg, 
Gemany). Protein concentrations were calculated by generating a standard curve 
from the measured absorbance of the standard concentrations using MARS data 
analysis software. 
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2.5.3 Discontinuous sodium dodecyl sulfate - polyacrylamide gel 
electrophoresis (SDS-PAGE) 
 
3x Sample buffer 90 mM Tris/HCl, pH 6.8 
 7 % SDS 
 30 % Glycerol 
 20 % β-mercaptoethanol 
 Bromphenol blue 
 in H2Obidest 
 
20x NuPAGE MOPS SDS 50 mM MOPS 
Running Buffer 50 mM Tris 
(Thermo Scientific, Waltham, 0.1 % SDS 
USA) 1 mM EDTA 
 pH 7.7 
 
10x Tris/Glycine/SDS 25 mM Tris 
Electrophoresis Buffer 192 mM Glycine 
(BioRAD, Hercules, USA) 0.1 % SDS 
 pH 6.8 
 
4x NuPAGE LDS Sample Buffer Thermo Scientific, Waltham, USA 
NuPAGE 12 % Bis-Tris Protein Thermo Scientific, Waltham, USA 
Gels  
Any kD Mini-PROTEAN BioRAD, Hercules, USA 
TGX Precast Gels 
PageRuler Plus Prestained Thermo Scientific, Waltham, USA 
Protein Ladder 
InstantBlue Protein Stain C.B.S Scientific, San Diego, USA 
 
To separate proteins by size, SDS-PAGE was performed. The BioRAD system was 
used for all protein samples, except for the limited proteolysis samples that were run 
on 12 % NuPAGE gels, as a higher resolution was required. For both systems, 
protein samples were mixed with their respective sample buffer and heated for 5 min 
or 10 min (in the case of limited proteolysis experiments) at 95 °C. Samples and 4 µl 
of marker were loaded onto the gel and run at 30 mA for 1 h (Any kD Mini-PROTEAN 
TGX Precast Gels) or 2.5 h (NuPAGE 12 % Bis-Tris Protein Gels). Gels were either 
stained with InstantBlue or further used for Western Blotting. To directly detect 
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proteins, gels were stained with InstantBlue for 15 – 60 min and afterwards washed 
with H2Obidest.  
 
2.5.4 Sedimentation assay 
 
Lysis Buffer  10 mM Tris/HCl, pH 7.5 
 100 mM NaCl 
 10 mM EDTA 
 0.5 % Triton X-100 
 0.5 % Sodium Deoxycholate 
 Protease inhibitor (complete, EDTA free, Roche 
Diagnostics, Basel, Switzerland) 
 
TNE Buffer 50 mM Tris/HCl, pH 7.5 
 150 mM NaCl 
 5 mM EDTA 
 
For the sedimentation assay, cells were plated on 6 cm dishes for 24 h and, 
depending on the assay, incubated with 10 µM in vitro fibrillized NM (monomer 
concentration) for 24 h (2.4.8) or left untreated. Cells were detached as described 
(2.4.2) and lysed in 200 µl lysis buffer for 20 min on ice. Cell lysates were centrifuged 
at 1000 x g for 1 min at 4 °C to remove cell debris (Eppendorf Centrifuge 5417R, 
Hamburg, Germany). To separate the soluble from the insoluble fraction, the 
supernatant was centrifuged at 20000 x g for 20 min at 4 °C. Proteins in the soluble 
supernatant fraction were precipitated with Methanol O/N at -20 °C. The insoluble 
pellet fraction was washed once with lysis buffer and the centrifugation step was 
repeated. The pellet was stored at -20 °C. The following day, the precipitated soluble 
fraction was centrifuged at 2120 x g for 25 min at 4 °C and the supernatant 
discarded. The insoluble and soluble fractions were resuspended in 17 µl or 100 µl 
TNE buffer, respectively. Fractions were supplemented with sample buffer and 
heated for 5 min at 95 °C as described (2.5.3). The entire insoluble and 1/6 of the 
soluble fraction were loaded onto SDS gels.  
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2.5.5 Semi-denaturing detergent - agarose gel electrophoresis (SDD-AGE) 
 
Lysis Buffer 50 mM Tris/HCl, pH 7.5 
 150 mM NaCl 
 1 % NP-40 
 Protease inhibitor (complete, EDTA free, Roche 
Diagnostics, Basel, Switzerland) 
 
4x Sample Buffer 2x TAE buffer (2.3.4) 
 20 % Glycerol 
 8 % SDS 
 Bromphenol blue 
 
Running Buffer 1x TAE buffer  
 0.1 % SDS 
 
TBS 25 mM Tris/HCl, pH 7.6 
 137 mM NaCl 
 in H2Obidest 
 
Thick blot filter papers BioRAD, Hercules, USA  
Protran BA 83 Nitrocellulose Whatman, Maidstone, UK 
0.2 µm 
 
To verify the amyloid nature of NM aggregates, the SDD-AGE assay (Kryndushkin et 
al. 2003) was performed. Cells were harvested as described (2.4.2) and lysed for    
30 min on ice (T75 – flasks: 50 – 500 µl lysis buffer, depending on the expression 
level of the individual protein). Cell debris was removed by centrifugation at 514 x g 
for 2 min at 4 °C (Eppendorf Centrifuge 5417R, Hamburg, Germany). The 
supernatant was incubated with sample buffer for 5 min at RT. Samples were loaded 
on an 1.5 % agarose gel supplemented with 0.1 % SDS submerged in running buffer 
to separate monomeric and SDS-resistant protein polymers. The gel was run at 15 V 
O/N at 4 °C in an electrophoresis chamber (Peqlab, Erlangen, Germany). On the 
following day, a nitrocellulose membrane, ten thick blot filter papers and eight 
whatman papers were cut into the size of the gel. The membrane, four of the 
whatman papers and one long whatman paper, to be used as a wick, were immerged 
in TBS. The agarose gel was briefly washed with water to remove excess running 
buffer. Ten dry thick blot filter papers, four dry whatman papers, one pre-wetted 
whatman paper and the membrane were stacked in a dry electrophoresis chamber 
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on top of each other. The agarose gel was carefully slid onto the membrane taking 
care to avoid bubble formation under the gel that would hinder the transfer. The three 
remaining pre-wetted whatman papers were placed on top of the gel. The wick was 
draped on top of the stack with both ends immerged in TBS. As a weight, a full      
500 ml glass bottle was placed on top and capillary transfer proceeded O/N at RT. 
On the next day, the membrane was further processed by standard Western blotting 
methods (2.5.7). 
 
2.5.6 Limited proteolysis  
 
Lysis Buffer 50 mM Tris/HCl, pH 7.5 
 150 mM NaCl 
 0.5 % NP-40 
 
1 % Pefabloc Roche, Mannheim, Germany 
 in H2Obidest 
 
Cells were harvested as described (2.4.2) and lysed in lysis buffer (1/3 T75 – flask: 
80 µl) on ice for 30 min. Cell debris was spun down at 514 x g for 2 min at 4 °C 
(Eppendorf Centrifuge 5417R, Hamburg, Germany) and the protein concentration of 
the supernatant was determined as described (2.5.2). Protein lysates (100 – 300 µg 
protein) and in vitro fibrillized recombinant NM (500 ng) (2.4.8) were partially digested 
with the appropriate amount of freshly thawed chymotrypsin for 1 h on ice using 
protein:protease ratios between 1:250 - 1:1000 (cell lysates) and 1:1 – 1:50000 (NM 
fibrils) in a total volume of 25 – 50 µl. The reaction was stopped by addition of           
1 % Pefabloc (0.04 % final concentration) and the appropriate amount of 4x SEB 
buffer. Samples were heated for 10 min at 95 °C and loaded onto 12 % SDS gels. 
The gel was afterwards processed by standard Western blotting methods (2.5.7). 
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2.5.7 Immunochemical detection of proteins via Western blot 
 
1x Blotting buffer 20 % Methanol 
 25 mM Tris 
 192 mM Glycine 
 in H2Obidest 
 
10x TBST 250 mM Tris/HCl, pH 7.6 
 1.37 M NaCl 
 0.05 % TWEEN-20 
 in H2Obidest 
 
Protran BA 83 nitrocellulose Whatman, Maidstone, UK 
0.2 µm 
Pierce ECL solution Thermo Scientific, Waltham, USA 
Amersham ECL Prime Western GE Healthcare Life Sciences, Chicago, 
Blotting Detection Reagent USA 
10x ReBlot Plus Strong Antibody Merck Millipore, Billerica, USA 
Stripping Solution 
 
SDS gels were prepared as previously described (2.5.3). For Western blotting, a 
nitrocellulose membrane and six whatman papers were cut to the size of the gel and 
pre-equilibrated in blotting buffer together with the gel. Gel, membrane, whatman 
papers and 2 pre-wetted sponge pads were stacked in perforated plastic plates and 
placed into a wet blotter (PerfectBlue, Tank-Electroblotter Web, Peqlab, Erlangen, 
Germany). The electric protein transfer was conducted at 300 mA for 60 min (Perfect 
Blue small) or 800 mA for 70 min (Perfect Blue medium). After blotting, the 
membrane was blocked in 5 % milk powder in 1x TBST for 60 minutes. The blocking 
buffer was discarded and the membrane was incubated with the primary antibody 
diluted in blocking buffer O/N at 4 °C (Table 6). The next day, unbound antibody was 
removed by washing three times in 1x TBST for 10 min. After the washing steps, the 
membrane was incubated with the corresponding secondary HRP-conjugated 
antibody diluted in blocking buffer for 1 h at RT (Table 7). The membrane was 
washed three times in 1x TBST for 10 min and afterwards incubated in 2 ml ECL 
solution for 1 min. The membrane was placed between a transparent plastic wrap 
and the light signal of the luminescence reaction was detected using a 
transilluminator machine (Stella, Raytest, Straubenhardt, Germany). 
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To detect a second protein of interest, the membrane was stripped to remove bound 
antibodies. To this end, the membrane was washed with H2Obidest for 10 min and 
afterwards incubated twice with 1x ReBlot Plus Strong Antibody Stripping Solution 
(1:10 in H2Obidest) for 20 min. The membrane was washed three times with 1x TBST, 
blocked in blocking buffer for 30 min and incubated with the respective antibodies as 
described above. 
 
2.5.8 Production and purification of recombinant NM protein 
 
Protein Purification Buffer A 10 mM Tris/HCl, pH 7.2 
 8 M Urea 
in H2Obidest 
 
Protein Purification Buffer B 10 mM Tris/HCl, pH 7.2 
 8 M Urea 
 1 M NaCl 
in H2Obidest 
 
Protein Purification Buffer C 5 mM KPhos, pH 7.2 
 8 M Urea 
in H2Obidest 
 
Protein Purification Buffer D 500 mM KPhos, pH 7.2 
 8 M Urea 
in H2Obidest 
 
Table 8: Program Q-sepharose and CHT resin columns 
 
Time in min Flow ml/min % Buffer B/D 
0 3.0 5 
30 3.0 10 
90 3.0 50 
105 3.0 99 
120 3.0 100 
 
To produce recombinant NM protein, BL21 E.coli were transformed with the 
pNOTAG-NM plasmid as described (2.3.7). The following day, all bacteria colonies 
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were collected and used to inoculate 3 l LB medium supplemented with 100 µg/ml 
Ampicillin. The bacteria were shaken at 180 rpm and 37 °C (LT-X Lab-Therm, 
Kuhner Shaker, Aachen, Germany) until an OD600 of 0.6 was reached. At that point, 
gene expression was induced by addition of 1 M IPTG and the bacteria were shaken 
at 180 rpm for 3 - 4 h at 30 °C (LT-X Lab-Therm, Kuhner Shaker, Aachen, Germany). 
The bacteria were spun down at 3488 x g for 15 min at RT (Heraeus Multifuge X3R, 
Thermo Scientific, Waltham, USA), the supernatant was discarded and the pellet 
directly used or stored at -80 °C until further use. The bacteria pellet from 1 l of 
culture was resuspended in 50 ml of buffer A and lysed at 180 rpm for at least 30 min 
at 37 °C (LT-X Lab-Therm, Kuhner Shaker, Aachen, Germany). Afterwards, the 
suspension was centrifuged at 30000 x g for 20 min at 25 °C to remove any insoluble 
material. The supernatant was applied to a Q-sepharose column pre-equilibrated with 
buffer A. Unbound material was removed by washing with 5 column volumes of 
buffer A. Proteins were gradually eluted according to their ionic strength by applying 
a gradient of buffer A and B (Table 8). The eluted material was collected in 5 ml 
fractions that were analyzed by SDS-PAGE as described (2.5.3). Fractions 
containing the NM protein were pooled and loaded onto a CHT resin column         
pre-equilibrated with buffer C. The column was washed with 2 column volumes of 
buffer C to remove unbound material. The bound protein was eluted from the CHT 
resin by applying a gradient of buffer C and D (Table 8). Samples were again 
collected in 5 ml fractions and their protein content was analyzed by SDS-PAGE. 
Fractions containing the NM protein were pooled and dialyzed three times against   
1x PBS at 4 °C. Protein concentration was determined and 1 ml aliquots with a 
concentration of 100 µM (monomer concentration) were stored at -80 °C. 
 
2.6 Image data analysis and statistics 
 
2.6.1 Image data analysis 
 
Confocal images captured with the LSM 700, upright LSM 700 or wide-field 
fluorescence microscope (Zeiss, Jena, Germany) were processed using Zen 2010 
(black edition) or Zen 2012 (blue edition) software (Zeiss, Jena, Germany). For 
statistical analysis, confocal image sets were obtained using the Cell Voyager 
CV6000 (Yokogawa, Tokyo, Japan) with 40x magnification. Images were analyzed 
with Cell Profiler 2.1 image analysis software. To this end, an image analysis routine 
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was developed. In brief, nuclei and the corresponding cytoplasm were identified 
based on morphology parameters and the intensity of Hoechst 33342 and HCS 
CellMask staining, respectively. Full-length and mutant NM expressing cells were 
distinguished from non-expressing cells by intensity levels of immunofluorescently 
labeled NM. To identify aggregates, pixels were classified using the Ilastik 
segmentation toolkit. The number of full-length or mutant NM expressing cells as well 
as aggregate bearing cells was determined. 
 
2.6.2 Statistical analysis 
 
All data displayed in bar graphs are depicted as the mean. For statistically analyzed 
data, at least three biological replicates (n ≥ 3) were analyzed and at least 5000 cells 
per cell population were imaged. Error bars represent the standard deviation (SD) or 
the upper limit of the confidence interval as indicated. For statistical analysis the 
Cochran-Mantel-Haenszel test with continuity correction or the t-test were used as 
indicated. Longitudinal analysis of aggregate loss was performed using Cox 
proportional hazard model. A p-value of ≤ 0.05 was considered statistically 
significant. 
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3. Results 
 
3.1 Determining the prion domain of NM in mammalian cells 
 
Sup35 is the best-studied yeast prion to date and it is comprised of three domains. In 
prior studies, the carboxyterminal C domain was found to encode the translation 
termination function of the protein, whereas the aminoterminal N domain and the 
middle M domain were reported to encode its prion propensities (Ter-Avanesyan et 
al. 1993, Ter-Avanesyan et al. 1994, Liu et al. 2002). Previous studies have already 
shown that NM is able to propagate as a prion in mammalian cells (Krammer et al. 
2009, Hofmann et al. 2013), demonstrating the capacity of mammalian cells to 
replicate cytosolic prions. Since then, reports have further confined the PrD to the N 
domain and, depending on the publication, different amino acid stretches within this 
region. In mammalian cells however, no such definition of the PrD has been 
published so far. To first analyze whether the propensity to form polymers in 
mammalian cells is encoded in only one of the two domains, we constructed one 
mutant encoding only the N domain, one mutant encoding only the M domain and 
one mutant coding for NM ∆ 138-250, which has been shown to maintain the prion 
phenotype in S. cerevisiae (Bradley and Liebman 2004) (Fig. 6A). All constructs were 
carboxyterminally tagged with either an HA-tag (full-length NM) or a Myc-tag 
(mutants). To first explore the expression of full-length NM and the three mutants, we 
transiently transfected N2a cells and analyzed them by immunofluorescence staining 
after 48 h (Fig. 6B). Full-length NM and all mutants showed diffuse cytosolic 
expression. Interestingly, mutants with deletions of the entire or part of the M domain 
were also expressed in the nucleus, suggesting that the M domain helps to retain NM 
in the cytosol. 
It was previously shown that in vitro fibrillized recombinant NM seeds can enter the 
cell and induce aggregation of endogenous NM in yeast as well as in mammalian 
cells (King and Diaz-Avalos 2004, Tanaka et al. 2004, Krammer et al. 2009). To test 
if aggregation could be induced in our three mutants, we transiently transfected N2a 
cells with full-length NM and the three deletion mutants and incubated them 48 h post 
transfection with in vitro fibrillized recombinant NM for 24 h (Fig. 7A). Full-length NM 
and the three mutants demonstrated punctate aggregates in the cytosol (Fig. 7B). 
 
Results 
 41 
 
 
 
Figure 6. Full-length NM and mutants are expressed and retain their soluble state.    
(A) Scheme of full-length NM and the three deletion mutant constructs: NM, encoding the 
entire N and M domain; N, with a deletion of the entire M domain; NM ∆ 138-250, with a 
deletion of the entire M domain except for the first 14 amino acids; M, with a deletion of the 
entire N domain. Numbers refer to amino acids. (B) Immunofluorescence staining of N2a 
cells transiently transfected with full-length NM and mutants for 48 h. NM was detected using 
either mAb anti-HA or pAb anti-Myc as indicated (red). Nuclei were visualized with Hoechst 
(blue). Scale bar: 5 µm. 
 
Only the mutant lacking the entire N domain remained diffusely expressed without 
any signs of aggregation. Noticeably, mutants with an entire or partial deletion of the 
M domain showed punctate aggregates in the nucleus in addition to the cytosol   
(Fig. 7B, arrows). A finding that is in line with the previously observed expression 
pattern. 
To determine whether aggregation could also be induced by endogenous NM prions, 
we transiently transfected N2a cell clone 2CG11 stably producing NM-GFP 
aggregates (Hofmann et al. 2013) with full-length NM and the three deletion mutants 
(Fig. 8A). Full-length NM and the mutants showed decoration of the endogenous  
NM-GFP prions in the cytosol. As before, only the deletion mutant encoding only the 
M domain remained diffusely expressed without colocalization with NM-GFP 
aggregates. In line with previous results, mutants with deletions of the entire or part 
of the M domain also displayed aggregates in the nucleus (Fig. 8B, arrows). 
Interestingly, in those cells, NM-GFP aggregates were only detected in the cytosol.  
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Figure 7. Aggregate induction by addition of exogenous recombinant NM fibrils.       
(A) Experimental setup. N2a cells were transiently transfected with full-length NM or mutants 
and incubated after 48 h with 10 µM (monomer concentration) in vitro fibrillized recombinant 
NM for 24 h. (B) Immunofluorescence staining of transiently transfected N2a cells. NM was 
detected using either mAb anti-HA or pAb anti-Myc as indicated (red). Nuclei were visualized 
with Hoechst (blue). Arrows mark intranuclear aggregates. Scale bar: 5 µm. 
 
To rule out the possibility that the sizable GFP-tag sterically hindered aggregate 
induction, we performed the same experiment with N2a cell clone NM-HAagg 5A 
stably producing NM-HA aggregates (Fig. 9). Confirming the previous results, 
mutants with a deletion of the entire or part of the M domain showed decoration of 
the endogenous NM-HA aggregates in the cytosol and additionally punctate 
intranuclear aggregates (Fig. 9, arrows). Again, no colocalization with endogenous 
aggregates could be observed for the mutant encoding only the M domain. 
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Figure 8. Aggregate decoration of endogenous NM-GFP prions. (A) Experimental setup. 
N2a cells stably producing NM-GFP prions were transiently transfected with full-length NM or 
mutant constructs for 48 h. (B) Immunofluorescence staining of N2a cell clone NM-GFPagg 
2CG11 transiently transfected with full-length NM or mutant constructs. NM was detected 
using either mAb anti-HA or pAb anti-Myc as indicated (red). GFP is depicted in green. 
Nuclei were visualized with Hoechst (blue). Arrows mark intranuclear aggregates. Scale bar: 
5 µm. 
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Figure 9. Aggregate decoration of endogenous NM-HA prions. Immunofluorescence 
staining of N2a cell clone NM-HAagg 5A transiently transfected with mutant constructs for     
48 h. NM was detected using either pAb anti-Myc (red) or mAb anti-HA (green) as depicted. 
Nuclei were visualized with Hoechst (blue). Arrows mark intranuclear aggregates. Scale bar: 
5 µm. 
 
In summary, these findings demonstrate that the M domain itself is not capable of 
forming self-replicating polymers whether induced by exogenous fibrils or 
endogenous prions. The N domain on the other hand is sufficient to form aggregates 
and carries the PrD of NM in mammalian cells as well as in yeast. Nevertheless, 
intracellular localization of the protein appears to be influenced by expression of the 
M domain. Based on these results we decided to focus the identification of functional 
domains crucial for cytosolic prion replication on the N domain, albeit also expressing 
the M domain to restrict expression to the cytoplasm. 
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3.2 Generation of N2a cell lines stably expressing full-length NM and NM 
mutants 
 
To identify functional regions required for cytosolic prion replication within the N 
domain of Sup35, eight NM mutants were generated based on mutants that had 
previously been studied in yeast (Osherovich et al. 2004): NM ∆ 1-39, lacking the 
QNR; NM ∆ 39-123, with a deletion of the entire OPR (R1 – R6) and the CTN; NM    
∆ 75-123, lacking repeats 4 – 6 and the CTN; NM ∆ 98-123, lacking only the CTN; 
NM G58D, carrying a point mutation in repeat 2; NM ∆ 39-57, with a deletion of 
repeat 1 and partially of repeat 2; NM ∆ 39-74, lacking repeats 1 - 3 and NM ∆ 75-97, 
with a deletion of repeats 4 – 6 (Fig. 10). 
 
 
 
 
Figure 10. Scheme of full-length NM and NM mutants. Full-length NM and eight NM 
mutants were analyzed in this study. QNR: aa 1-39, R1: aa 41-49, R2: aa 56-64, R3:          
aa 65-74, R4: aa 75-83, R5: aa 84-93, R6: aa 94-97, CTN: aa 98-123. NM ∆ 1-39, with a 
deletion of the QNR; NM ∆ 39-123, with a deletion of the entire OPR (R1 – R6) and the CTN; 
NM ∆ 75-123, with a deletion of repeats 4 – 6 and the CTN; NM ∆ 98-123, with a deletion of 
the CTN; NM G58D, with a glycine to aspartic acid point mutation in repeat 2; NM ∆ 39-57, 
with a deletion of repeat 1 and part of repeat 2; NM ∆ 39-74, with a deletion of repeat 1 – 3 
and NM ∆ 75-97, with a deletion of repeats 4 – 6. Numbers refer to amino acids. 
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The NM mutants were generated using mutation specific primers or were purchased 
from the indicated manufacturers (methods, Table 2 and 3). NM constructs were 
carboxyterminally tagged with an HA-tag and cloned into the mammalian expression 
vector pJ602. To generate stable cell lines expressing full-length NM and NM 
mutants using lentiviral transduction, NM constructs were additionally cloned into the 
lentiviral expression vector pRRL.sin.PPT.CMV.Wpre (Follenzi and Naldini 2002). 
To obtain stable cell lines expressing full-length NM and NM mutants, we produced 
lentiviral particles encoding the NM constructs. N2a cells were transduced with the 
lentiviral particles and analyzed by immunofluorescence staining (Fig. 11A). 
 
 
 
 
Figure 11. N2a cells stably express full-length NM and NM mutants.                             
(A) Immunofluorescence staining of N2a cells stably expressing full-length NM and NM 
mutants. NM was detected using mAb anti-HA (red). Nuclei were visualized with Hoechst 
(blue). Scale bar: 5 µm. (B) Percentage of cells in the bulk population (passage one post 
thawing) expressing full-length and mutant NM. Bars represent mean values ± SD (n = 3). 
 
All cell lines showed stable and diffuse ectopic expression of full-length and mutant 
NM throughout the cytosol. No expression in the nucleus was detected. We 
performed high-throughput analysis to determine the transduction rate of the stable 
full-length and mutant NM-HA cell lines. To this end, we stained the cells in a          
96 - well plate and imaged them with an automated confocal microscope (Cell 
Voyager 6000, Yokogawa, Tokyo, Japan) (methods, 2.4.7). Image analysis was 
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performed using the Cell Profiler cell image analysis software (methods, 2.6.1). The 
analysis demonstrated that at least ~ 48 % of the cells showed clear expression of 
full-length NM and NM mutants (Fig. 11B). 
These initial results demonstrate the generation of a useful tool for further studies on 
functional domains for cytosolic prion replication in a mammalian cell line. 
 
3.3 Deletion of the QNR increases the rate of spontaneous aggregation  
 
The previous images showed that full-length NM and NM mutants are diffusely 
expressed throughout the cytosol. However, upon closer examination of the 
immunofluorescence data, in individual cells spontaneously formed aggregates were 
detected in cell line NM-HA ∆ 1-39 (Fig. 12A). 
 
 
 
 
 
Figure 12. Deletion of the QNR increases the rate of spontaneous aggregation.          
(A) Immunofluorescence staining of the stable N2a cell line expressing NM-HA ∆ 1-39. NM 
was detected using mAb anti-HA (red). Nuclei were visualized with Hoechst (blue). Scale 
bar: 5 µm. (B) Percentage of cells that express the transgene and spontaneously form NM 
aggregates at passage one post thawing. Bars represent mean values ± SD (n = 3, three 
individual cryogenic vials were thawed). At least 14000 cells were imaged per cell population. 
For statistical analysis the Cochran-Mantel-Haenszel test was performed (* p ≤ 0.05,            
** p ≤ 0.01, **** p ≤ 0.0001, ns: not significant). 
 
To determine the frequency of spontaneous aggregation in full-length NM and NM 
mutant cell lines, we performed high-throughput analysis of the cell populations at 
passage one post thawing (Fig. 12B). The quantitative assessment showed that 
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approximately 2.5 % of cells expressing NM ∆ 1-39 were bearing NM aggregates, 
whereas aggregates were rare in the other cell lines. Only extremely rare events      
(≤ 0.2 %) were detected for full-length NM or NM mutants with deletions within the 
OPR (NM ∆ 39-57, NM ∆ 39-74, NM ∆ 75-97). However, lowest spontaneous 
aggregation frequencies (≤ 0.02 %) were detected for NM mutants lacking the last 
three repeats of the OPR and/or the CTN (NM ∆ 39-123, NM ∆ 75-123, NM               
∆ 98-123). 
To verify the aggregation state of full-length NM and NM mutants, we separated 
soluble from insoluble proteins by sedimentation assay and performed Western blot 
analysis (Fig. 13). 
 
 
 
 
Figure 13. Sedimentation assay of N2a cells stably expressing full-length NM or NM 
mutants. Sedimentation assay of N2a cell lines stably expressing full-length or mutant NM. 
NM was detected using mAb anti-HA. S: supernatant, P: pellet. 
 
All NM cell populations displayed a clear signal in the soluble fraction, confirming 
expression of full-length NM and NM mutants by biochemical analysis. Small size 
differences in the NM bands correspond to the deletions found in each mutant. Only 
NM ∆ 1-39 additionally showed a signal in the insoluble fraction, thereby verifying the 
aggregated nature of the observed spontaneously formed conformers. 
To determine if the rate of spontaneous aggregation would vary in consecutive 
passages and if spontaneously formed aggregates were stable over time, we 
quantitatively assessed the percentage of aggregate bearing cells at passage 1, 3, 5, 
7, 10 and 13 post thawing (Fig. 14). Generally, the highest percentage of cells 
harboring spontaneously formed aggregates was detected at passage one. Towards 
later passages, the amount of aggregate bearing cells was steadily decreasing, 
indicating that spontaneous aggregation is merely an early event and spontaneously 
formed aggregates do not accumulate over time. Lowest frequencies of 
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spontaneously formed aggregates were again detected for NM mutants lacking the 
last three repeats of the OPR and/or the CTN (NM ∆ 39-123, NM ∆ 75-123, NM        
∆ 98-123). 
 
 
 
 
 
Figure 14. Spontaneous aggregation of full-length NM and NM mutants over 
consecutive passages. Quantitative analysis of cells that express the NM transgene and 
spontaneously form aggregates at passage 1, 3, 5, 7, 10, 13 post thawing. Note variations in 
scaling. Bars represent mean values ± SD (n = 3).  P: passage.  
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In yeast, the frequency of prion induction is increased with a higher expression level 
of the respective prion protein (Derkatch et al. 1996). To analyze whether the 
elevated rate of spontaneous aggregation observed in N2a cell line NM-HA ∆ 1-39 
was due to higher expression of the NM mutant, we first determined full-length NM 
and NM mutant expression levels in the stable cell populations (Fig. 15) 
 
 
 
 
 
 
Figure 15. Expression of full-length NM and NM mutants in stable cell populations. 
Expression levels of full-length NM or NM mutants in N2a cell populations. NM was detected 
using mAb anti-HA. Actin was visualized with mAb anti-actin. 
 
Differences in the expression levels correlated with the percentage of cells 
expressing full-length and mutant NM in the stable N2a cell populations (Fig. 11B, 
15). The slight banding pattern visible underneath some NM signals is most likely 
due to protein degradation observed already by Paushkin and colleagues in 1996 
(Paushkin et al. 1996). To test the influence of expression levels on the rate of 
spontaneous aggregation, we transiently transfected N2a cell populations expressing 
full-length NM and NM mutants ∆ 75-123 and ∆ 98-123 with expression plasmids 
encoding the same NM construct (Fig. 16A). Upon transient transfection the 
expression was increased almost three-fold in all cell populations (Fig. 16B). 
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Figure 16. Expression levels of full-length NM and NM mutants upon transient 
transfection of stable N2a cell populations. N2a cell populations expressing full-length 
NM and NM mutants ∆ 75-123 or ∆ 98-123 were transiently transfected with expression 
plasmids encoding the respective NM protein. (A) Ctrl: cell populations before transfection, 
transf: same cell population after transfection with the respective NM construct. NM was 
detected with mAb anti-HA. Actin was visualized with mAb anti-actin. (B) Quantitative 
analysis of NM expression shown in A (three separate transfections). For statistical analysis, 
the t-test was performed (** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001). 
 
We performed high-throughput analysis of the control und transiently transfected cell 
populations (Fig. 17) and detected that the rate of spontaneous aggregation was only 
insignificantly altered, indicating that the expression level itself was not the cause for 
the increase in spontaneously formed aggregates in N2a cell line NM-HA ∆ 1-39. 
 
 
 
 
Figure 17. Influence of the expression level on spontaneous aggregation. Spontaneous 
aggregation of stable full-length and mutant NM expressing cell lines compared to the 
untransfected control cell lines. At least 5000 cells were analyzed per cell population. For 
statistical analysis, the Cochran-Mantel-Haenszel test was performed (n = 3, three separate 
transfections). At least 5000 cells were imaged per cell population Ctrl: control, ns: not 
significant.  
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In conclusion, the data indicate that the QNR helps to retain the prion precursor 
protein in its soluble state and has an inhibitory effect on aggregation in the 
mammalian cell environment.  
 
3.4 The last three repeats of the OPR and the CTN are essential for initial 
aggregate formation 
 
In the previous experiments, we could show that full-length NM and NM mutants 
were clearly expressed in the cytosol and, with very few exceptions, remained 
soluble throughout multiple passages. Next, to investigate which functional domains 
of NM are important for the induction of aggregates, we analyzed whether 
aggregation could be induced by endogenous NM-GFP prions. We therefore 
transiently transfected N2a cell clone 2CG11 stably producing NM-GFP aggregates 
with full-length NM and NM mutant constructs and screened the cells for NM-HA 
aggregates (Fig. 18). 
 
 
 
 
 
Figure 18. Experimental setup to study decoration of endogenous NM-GFP prions by 
NM-HA. N2a cell clone 2CG11 stably producing NM-GFP aggregates was transiently 
transfected with full-length NM or NM mutant constructs. Cells were fixed 48 h post 
transfection and screened for NM-HA aggregates. 
 
Colocalization of NM-HA with NM-GFP prions was observed for all NM mutants, 
except for NM deletion mutant NM ∆ 39-123, where aggregation was essentially 
abolished (≤ 1%) (Fig. 19). Though all except one NM mutant showed clear 
decoration of endogenous NM-GFP prions, decoration efficiencies appeared to be 
highly divers.  
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Figure 19. Full-length NM and NM mutants colocalize with endogenous NM-GFP 
prions. Immunofluorescence staining of N2a cell clone 2CG11 stably producing NM-GFP 
prions transiently transfected with HA-tagged full-length NM or NM mutant constructs. Cells 
were fixed 48 h post transfection. NM was detected using mAb anti-HA (red). GFP is 
depicted in green. Nuclei were visualized with Hoechst (blue). Note that some NM-GFP 
aggregates also brightly stained with Hoechst. Arrows mark NM-HA aggregate puncta not 
colocalizing with NM-GFP prions. Scale bar: 5 µm. 
 
For full-length NM, NM ∆ 1-39, NM G58D and NM deletion mutants with a deletion of 
the aminoterminal OPR (NM ∆ 39-57, NM ∆ 39-74) a high majority of cells showed 
decoration of NM-GFP prions (≥ 50%). For NM mutants with a deletion of the 
carboxyterminal OPR and/or CTN (NM ∆ 75-123, NM ∆ 98-123, NM ∆ 75-97) only 
very few cells with NM-HA aggregates were found (≤ 5%). Interestingly, in those cell 
lines aggregates only partially colocalized with NM-GFP prions. Small NM-HA 
aggregate puncta were often found separated from NM-GFP aggregates (Fig. 19, 
arrows), suggesting that NM-GFP prions could template the conversion to the 
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aggregated NM-HA isoform but only inefficiently co-aggregated with those NM 
mutants. Note that large NM-GFP aggregates occasionally stained with the      
double-stranded DNA dye Hoechst, probably due to dye being trapped in high 
molecular weight conformers. 
To analyze if aggregation of ectopically expressed NM could also be induced by 
addition of exogenous seeds, we induced aggregation of full-length NM and NM 
mutants in the stable N2a cell lines by incubation with in vitro fibrillized recombinant 
NM (Fig. 20A). 
 
 
 
 
Figure 20. Exogenous NM fibrils induce full-length NM and NM mutant aggregates.   
(A) Experimental setup. N2a cells stably expressing full-length NM or NM mutants were 
incubated with 1 µM (monomer concentration) in vitro fibrillized NM for 24 h.                       
(B) Immunofluorescence staining of N2a cells stably expressing full-length NM or NM 
mutants incubated with NM fibrils. NM was detected using mAb anti-HA (red). Nuclei were 
visualized with Hoechst (blue). Scale bar: 5 µm. Note that recombinant NM fibrils do not stain 
with mAb anti-HA. 
 
Punctate aggregates were found in full-length NM and all NM mutant cell populations 
(Fig. 20B). Aggregates sometimes clustered together near the nucleus and at times 
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were spread throughout the entire cytosol. However, no localization could directly be 
attributed to one NM mutant.  
To confirm the aggregation state of NM, we performed sedimentation assays using 
the stable full-length or mutant NM expressing cell lines 24 h after induction with        
in vitro fibrillized recombinant NM (Fig. 21).  
 
 
 
 
 
Figure 21. Sedimentation assay of stable N2a cells expressing full-length NM or NM 
mutants after induction with NM fibrils. Sedimentation assay of stable N2a cell lines 
expressing full-length and mutant NM incubated with 10 µM (monomer concentration) in vitro 
fibrillized NM for 24 h. NM was detected using mAb anti-HA. Additional lanes were excised 
for presentation purposes as indicated by the dotted line. S: supernatant, P: pellet. 
 
For full-length NM and all NM mutants, a signal in the insoluble fraction was 
detected, confirming the aggregated state of the observed puncta. Interestingly, 
though aggregates were clearly formed, a major part of the protein was still found in 
the soluble fraction, indicating that not the entire pool of NM was converted into 
insoluble conformers. The amount of insoluble protein in full-length NM and NM 
mutants showed great differences, indicating that aggregate induction efficiencies 
varied between the NM mutants. 
To quantify the induction efficiencies in full-length NM and NM mutants, we 
performed high-throughput analysis on the stable N2a cell lines at passage one after 
aggregate induction by in vitro fibrillized recombinant NM (Fig. 22).  
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Figure 22. Aggregate induction efficiencies of full-length NM and NM mutants. Stable 
N2a cells expressing full-length NM and NM mutants were incubated with 10 µM (monomer 
concentration) recombinant NM fibrils for 24 h and analyzed by immunofluorescence staining 
at passage one post induction. Bars represent mean values ± SD (n = 3, three separate 
induction experiments). At least 12500 cells per cell population were imaged. For statistical 
analysis the Cochran-Mantel-Haenszel test was performed (**** p ≤ 0.0001). 
 
In full-length NM expressing cells aggregates were detected in approximately 60 % of 
the cells. Comparable results were observed for NM mutants with either a deletion of 
the QNR or a point mutation in the second repeat (NM ∆ 1-39: 58 %, NM G58D:       
54 %). NM mutants lacking only part of the OPR showed a reduced number of 
aggregate bearing cells compared to full-length NM and interestingly, the effect was 
more pronounced with a closer proximity of the deletion to the carboxyterminus of the 
N domain (NM ∆ 39-57: 46 %, NM ∆ 39-74: 41 %, NM ∆ 75-97: 12 %). The strongest 
effect was seen in NM mutants with deletions of the CTN with or without additional 
deletions of the last three repeats of the OPR (NM ∆ 39-123, NM ∆ 75-123, NM        
∆ 98-123, ≤ 5 %).  
In summary, the data demonstrates that the last three oligopeptide repeats and the 
CTN play a major role for the template-mediated conformational change to the prion 
isoform. 
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3.5 The last three oligopeptide repeats and the CTN contribute to vertical 
transmission 
 
Our prior results showed that the last three repeats of the OPR and the CTN are of 
great importance for the templated conversion to the prion isoform. Besides 
aggregation, one striking feature of prions is the continual propagation of the prion 
phenotype to daughter cells. Propagation is facilitated by fragmentation of high 
molecular weight polymers into smaller entities (Krauss and Vorberg 2013). In cell 
culture models, functional fragmentation and propagation is determined by analyzing 
the amount of aggregate bearing cells over several passages. To assess the mitotic 
stability of the newly formed conformers, we analyzed stable N2a cells expressing 
full-length NM or NM mutants for nine passages after aggregate induction with NM 
fibrils (Fig. 23A). Full-length NM and NM mutants demonstrated the same variations 
in the initial amount of aggregate bearing cells as already observed in Figure 22      
(Fig. 23B). As before, full-length NM, NM with a deletion of the QNR and NM with a 
point mutation in the second repeat (NM ∆ 1-39 and NM G58D, respectively) showed 
the highest amount of aggregate bearing cells, whereas only few aggregates could 
be detected for NM mutants lacking the last three oligopeptide repeats and/or the 
CTN (NM ∆ 39-123, NM ∆ 75-123, NM ∆ 98-123, NM ∆ 75-97). Independent of the 
initial amount of cells with aggregates, full-length NM and NM mutants showed a 
gradual decline in aggregate bearing cells over time, which appeared to stabilize 
between passages six and nine for full-length NM, NM ∆ 1-39 and NM G58D. 
Interestingly, even in N2a cell populations with a very low initial number of aggregate 
bearing cells, few cells with aggregates could still be detected after nine passages.  
We used the Cox proportional hazard model to statistically analyze differences in the 
mitotic stability of NM mutants compared to full-length NM (Fig. 24). A higher fold 
change indicates a higher probability of aggregate bearing cells being lost over time. 
In general, mutations in NM decreased the mitotic stability of aggregates. NM 
mutants lacking the last three repeats of the OPR or the CTN (NM ∆ 98-123, NM      
∆ 75-97, fold change > 1) were the least heritable. 
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Figure 23. Full-length NM and NM mutant aggregates are maintained over several 
passages. (A) Experimental setup. Stable N2a cells expressing full-length NM or NM 
mutants were incubated with 10 µM (monomer concentration) in vitro fibrillized recombinant 
NM for 24 h and grown for nine passages. Cells at passage 1, 3, 6 and 9 were stained and 
analyzed by automated confocal microscopy. (B) Percentage of full-length NM or NM mutant 
expressing N2a cells harboring aggregates over consecutive passages (n = 3, three 
independent induction experiments). P: passage. 
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Figure 24. Fold change of the loss of NM mutant aggregate bearing cells over time 
compared to full-length NM. Fold change of the probability for NM mutant cell populations 
to loose aggregate harboring cells over time compared to full-length NM. Bars represent 
mean values. Error bars represent the upper limit for the confidence interval (n = 3). Ctrl: 
control. Cox proportional hazard model was performed for statistics (cell count >12500,                  
**** p ≤ 0.0001).  
 
However, a high fold change was also seen in NM mutant NM ∆ 75-123, lacking both 
regions, NM ∆ 39-57, lacking repeat 1 and parts of repeat 2, and NM ∆ 39-74, lacking 
repeats 1 – 3 (fold change > 0.5 and < 1). Interestingly, NM G58D showed even 
increased mitotic stability (fold change > -0.5 and < 0) compared to full-length NM, 
contradictory to previous findings where the point mutation resulted in prion loss in 
yeast (Kochneva-Pervukhova et al. 1998). These findings indicate, that in contrast to 
yeast, NM maintenance in mammalian cells does not depend on the second 
oligopeptide repeat. 
To directly examine the fate of full-length NM and NM mutant aggregates upon cell 
division, we generated N2a cell lines stably expressing full-length NM and NM 
mutants NM ∆ 1-39 and NM ∆ 75-123 with a carboxyterminal GFP-tag. Aggregation 
was induced by addition of recombinant NM fibrils and the cells were subsequently 
subjected to life cell imaging two passages post induction (Fig. 25). All cell 
populations showed distinct NM-GFP aggregates that were distributed to both 
daughter cells upon cell division, confirming that mutant NM, lacking either the QNR 
or the last three repeats and the CTN, could still be propagated to the progeny. 
In conclusion, these findings show that the last three repeats of the OPR and the 
CTN mainly contribute to mitotic stability of the prion isoform. 
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Figure 25. Full-length NM and NM mutant aggregates are bidirectionally transmitted to 
daughter cells. Time-lapse analysis of stable N2a cell lines expressing full-length NM or NM 
mutants Δ 1-39 and Δ 75-123 with a carboxyterminal GFP-tag (green). N2a cells were 
exposed to 10 µM (monomer concentration) recombinant NM fibrils for 24 h. Cells were 
subjected to life cell imaging for a total of 15 hours two passages post induction. Min: 
minutes; scale bar: 10 µm. 
 
3.6 NM mutants exhibit infectious properties and horizontally transmit 
the aggregate phenotype to bystander cells 
 
In contrast to their behavior in yeast, full-length NM prions were shown to infect 
neighboring cells and induce a self-perpetuating prion state (Hofmann et al. 2013). In 
the previous experiments we could already show that template-mediated aggregation 
and the subsequent propagation of aggregates were impaired by deletions of the last 
three oligopeptide repeats and the CTN, while deletion of the QNR had rather 
opposite effects. To further investigate the infectivity of mutated NM, we first had to 
increase the amount of aggregate bearing cells in our stable cell lines. Transfection 
reagents have already been shown to facilitate the uptake of fibrillized proteins into 
cells (Nonaka et al. 2010). Thus, we incubated the stable N2a cell lines expressing 
full-length NM or NM mutants with NM fibrils mixed with Effectene reagents (Fig. 26).  
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Figure 26. Increased aggregate induction efficiency by Effectene reagents. 10 µM        
(monomer concentration) in vitro fibrillized recombinant NM was solely or in combination with 
Effectene reagents added to stable N2a cells expressing full-length NM or NM mutants for  
24 h. Aggregate induction efficiencies were determined at passage three post induction. At 
least 400 cells per treatment were analyzed. 
 
Mixing NM fibrils with Effectene reagents drastically increased the induction rates in 
full-length NM and NM mutant expressing stable cell lines. Interestingly, the increase 
in aggregate bearing cells was not equal in all NM mutants. NM ∆ 39-123, lacking the 
entire OPR and the CTN, showed the most striking change, with an increase of over 
25-fold. Though the number of aggregate bearing cells was drastically increased for 
all NM mutants, the stable N2a cell line expressing NM ∆ 75-123 still exhibited less 
than 8 % of NM aggregate bearing cells. Thus, we performed limiting dilution cloning 
using the aggregate bearing full-length NM and NM ∆ 1-39 and NM ∆ 75-123 N2a 
bulk populations generated with the use of Effectene reagents to generate cell clones 
with a high number of aggregate bearing cells. For full-length NM, we analyzed a 
total of 24 clones, 14 of which produced aggregates in 80-100 % of the cells. For NM 
∆ 1-39, we tested 20 clones and obtained 16 clones stably propagating aggregates in        
80-100 % of total cells. Due to the low amount of aggregate bearing cells in the NM  
∆ 75-123 expressing cell line, we analyzed 144 clones but obtained only two clones 
with 40-70 % stably propagating aggregates, indicating deficits in mitotic stability. We 
therefore performed sub-cloning, using the two clones obtained after the first round of 
limiting dilution cloning. We screened 86 clones, 21 of which showed aggregates in 
at least 50 % of the cells. For full-length NM as well as the two NM mutants, four 
clones or subclones were chosen, exhibiting aggregates in over 80 % of the cells 
(Fig. 27). 
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Figure 27. Cloning strategy to isolate N2a cell clones with stably propagating NM 
aggregates. Full-length NM and NM mutant cell populations were exposed to 10 µM 
(monomer concentration) recombinant NM fibrils mixed with Effectene reagents. Single cell 
clones were subsequently isolated by limiting dilution cloning. For NM ∆ 75-123, a second 
cloning step was included as the first round resulted in clones with only weak mitotic stability 
of NM aggregates. For full-length NM and NM mutants, four clones/subclones were chosen 
that produced aggregates in over 80 % of total cells. 
 
Confocal microscopy analysis of the cell clones revealed morphological diverse 
aggregate phenotypes (Fig. 28). Most cell clones produced small punctate 
aggregates, whereas others contained larger, fibrillar conformers. In addition, in 
some of the clones aggregates appeared to be restricted to one area, whereas in 
others aggregation was observed throughout the entire cytosol. However, neither 
morphological phenotypes nor specific cellular localizations could be directly 
attributed to individual deletions in NM. Multiple stably propagating phenotypic 
aggregate variants were already observed in yeast as well as in mammalian cells 
(Tanaka et al. 2004, Krammer et al. 2009) and are most likely the result of variations 
in expression levels, clonal differences and the conformational diversity of the NM 
fibrils used to induce aggregation. 
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Figure 28. Full-length NM and NM mutant cell clones stably propagate NM aggregates. 
Confocal microscopy analysis of single cell clones isolated by limiting dilution cloning. For 
full-length and mutant NM four clones/subclones were analyzed. NM was detected using 
mAb anti-HA (red). Nuclei were stained with Hoechst (blue). Scale bar: 5 µm. 
 
To confirm the amyloid nature of the aggregates, we performed semi-denaturing 
detergent - agarose gel electrophoresis (SDD-AGE) (Kryndushkin et al. 2003). For 
full-length NM and the NM mutants one single cell clone and the corresponding 
soluble NM-HA expressing bulk cell line were analyzed (Fig. 29). A distinct 
monomeric signal was detected for all soluble NM-HA expressing bulk cell lines. The 
single cell clones on the other hand showed large SDS resistant smears, confirming 
the amyloidogenic nature of the NM aggregates. Interestingly, the amyloid bands of 
full-length NM and NM mutant cell clones showed differences in the dominant size of 
the amyloid, suggesting the occurrence of different variants. 
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Figure 29. Full-length NM and NM mutant cell clones produce NM aggregates of 
amyloid nature. SDD-AGE assay of cell lysates from N2a NM-HAagg clone 7A, ∆ 1-39 clone 
5D, ∆ 75-123 subclone 8H-23 and the corresponding soluble NM-HA expressing bulk cell 
lines. NM was detected using mAb anti-HA. 
 
Next, we used the full-length NM and NM mutant cell clones to investigate the 
infectivity of the NM aggregates. We therefore cocultured the aggregate bearing    
full-length NM and NM mutant cell clones with N2a cells expressing soluble NM-GFP 
for 42 h and screened for the appearance of NM-GFP aggregates (Fig. 30A).       
NM-GFP aggregates were induced by all cell clones except for NM-HAagg ∆ 75-123 
subclone 64H-3, exhibiting especially large aggregates (Fig. 30B). It was already 
shown that transmission of the aggregate phenotype to bystander cells appears to be 
more efficient when donor cells produce small punctate aggregates (Hofmann et al. 
2013), an observation that most likely explains the lack of infectivity of that specific 
clone. 
To detect differences in the infectivity of full-length and mutant NM, we performed 
quantitative assessment of the intercellular aggregate induction rate of full-length NM 
and NM mutant cell clones (Fig. 31). Collectively, the induction rates were very low 
for full-length NM and the NM mutants. However, NM deletion mutant NM ∆ 1-39 
showed a significantly higher induction rate in comparison to the full-length NM 
control, suggesting that the QNR has, if any, a rather inhibiting effect on aggregate 
dissemination. Notably, direct comparison of aggregate induction rates is challenging 
due to clonal effects that might influence intercellular transmission of the aggregate 
phenotype (Hofmann et al. 2013). 
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Figure 30. Coculture of N2a full-length and mutant NM-HAagg cell clones with N2a    
NM-GFPsol cells. (A) Experimental setup. Clones harboring NM-HA aggregates were 
cocultured with N2a cells expressing NM-GFP for 42 h on coverslips.                                  
(B) Immunofluorescence staining of N2a full-length or mutant NM-HAagg donor cell clones 
cocultured with N2a NM-GFPsol recipient cells. Images were screened for cells with NM-GFP 
aggregates. NM-HA was detected using mAb anti-HA (red). Nuclei were stained with 
Hoechst (blue). GFP is depicted in green. Note that large NM-GFP aggregates also brightly 
stained with Hoechst dye. Scale bar: 5 µm. 
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Figure 31. Quantification of the intercellular aggregate induction rate of full-length NM 
and NM mutant cell clones. Percentage of NM-GFP aggregate bearing recipient cells after 
42 h coculture with full-length NM and NM mutant donor cells. Bars represent mean values of 
the combined data from the four NM full-length and NM mutant clones/subclones ± SD        
(n = 4). Cell count > 79000, **** p ≤ 0.0001, ns: not significant, Cochran-Mantel-Haenszel 
test. 
 
In summary, these results demonstrate that neither the QNR nor the last three 
oligopeptide repeats and the CTN are essential for intercellular transmission of the 
prion phenotype. 
 
3.7 The QNR is not part of the proteolytic protected core of full-length NM 
aggregates 
 
In vitro, the first 40 residues of NM, including the QNR, were experimentally identified 
as the amyloid core (Toyama et al. 2007). However, previous results from our study 
suggest a rather insignificant role of the QNR in the process of aggregation. To 
determine the tightly packed core region in our NM aggregates, we performed limited 
proteolysis using cell lysates form N2a NM-HAagg clone 7A, ∆ 1-39 clone 5D,             
∆ 75-123 subclone 8H-23 and the respective NM-HA expressing soluble bulk cell 
lines (Fig. 32A). Cell lysates were digested with decreasing amounts of chymotrypsin 
with the protease to total protein ratio ranging from 1:250 to 1:1000. Chymotrypsin 
preferentially cleaves at the carboxyterminus of aromatic amino acids (phenylalanine, 
tryptophan, tyrosine), residues that are with one exception only found in the N 
domain (Fig. 32B). 
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Figure 32. Experimental setup to determine the amyloid core of full-length NM and NM 
mutants. (A) Limited proteolytic digestion of cell lysates from N2a cells expressing soluble 
NM or producing NM aggregates. Proteins were analyzed by SDS PAGE and Western Blot. 
WB: Western blot. (B) Preferential cleavage sites of chymotrypsin. Arrowheads mark 
cleavage sites. Dark grey: EcoRI restriction site, red: HA-tag. 
 
Aggregated full-length NM and NM mutant protein displayed a much higher 
resistance to proteolytic digestion compared to the soluble isoforms (Fig. 33), in line 
with previous reports (Paushkin et al. 1996). As expected, the level of degradation 
was increased with higher amounts of chymotrypsin, resulting in protein fragments 
with a lower molecular weight. Surprisingly, no degradation products were detected 
for NM-HAagg ∆ 1-39 and only weak fragments for ∆ 75-123, that were most likely the 
result of residual soluble protein. In undigested soluble full-length NM, a second band 
was visible approximately 7 kDa below the band representing full-length NM. A 
similar band pattern was detected for undigested soluble NM ∆ 75-123. Additional 
bands in the undigested samples with a lower molecular weight were most likely the 
result of partial degradation of the NM protein, resulting from the absence of protease 
inhibitor in the lysis buffer. To interpret and compare fragment sizes between         
full-length NM and NM mutants more precisely, we repeated the experiment and this 
time loaded the NM-HAsol and NM-HAagg samples on one gel each (Fig. 34). For 
aggregated full-length NM, a very low band (~ 30 kDa) that was most likely the result 
of residual soluble protein, and two only slightly digested fragments (~ 38, 41 kDa) in 
addition to the full-length protein appeared on the blot. Interestingly, the most 
prominent fragment (~ 38 kDa) had the same size as undigested NM ∆ 1-39.  
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Figure 33. Proteolytic digestion of soluble and aggregated full-length NM and NM 
mutants. Proteolytic digestion of cell lysates from N2a NM-HAagg clone 7A, ∆ 1-39 clone 5D, 
∆ 75-123 subclone 8H-23 and the corresponding soluble NM-HA expressing bulk cell lines. 
Cell lysates were treated with chymotrypsin at the indicated protease to total protein ratios or 
left untreated. For size comparison samples from cells expressing soluble full-length        
NM-HA/NM-HA mutants and aggregated full-length NM-HA/NM-HA mutants were loaded on 
the same gel. NM was detected using 4A5 anti-M domain antibody (epitope: aa 229-247). 
CHY: chymotrypsin. 
 
As chymotrypsin preferentially cleaves in the aminoterminal half of NM and proteins 
on the membrane were detected with an antibody binding the carboxyterminal M 
domain (aa 229-247), this finding suggests that in full-length NM the QNR region is 
accessible to digestion. 
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Figure 34. Comparing full-length NM and NM mutant aggregate structures by limited 
proteolysis. Proteolytic digestion of cell lysates from N2a NM-HAagg clone 7A, ∆ 1-39 clone 
5D, ∆ 75-123 subclone 8H-23 and the corresponding soluble NM-HA expressing bulk cell 
lines. Cell lysates were treated with chymotrypsin at the indicated protease to total protein 
ratios or left untreated. For size comparison full-length and mutant NM-HAsol or NM-HAagg 
samples were loaded on the same gel. NM was detected using 4A5 anti-M domain antibody. 
CHY: chymotrypsin. 
 
As there were no detectable digestion products for NM ∆ 1-39 and the intensity of the 
full-length NM ∆ 1-39 signal was not reduced with higher concentrations of 
chymotrypsin, the remaining protein (~ aa 40-250) appeared to be well protected 
within the conformer. For aggregated NM ∆ 75-123 only residual soluble protein was 
detected in addition to the full-length NM ∆ 75-123 protein (Fig. 34, upper panel). 
Although no additional fragments were detected for NM ∆ 75-123, the intensity of the 
full-length NM ∆ 75-123 band decreased with higher amounts of chymotrypsin, 
indicating that the aggregated full-length NM ∆ 75-123 protein was accessible to 
digestion, suggesting a more loosely packed aggregate compared to NM ∆ 1-39. 
Control group lysates of stable cell lines expressing soluble full-length and mutant 
NM displayed increasing levels of digestion with higher levels of chymotrypsin, 
demonstrating proteolytic digestion of full-length and mutant NM when peptide chains 
are easily accessible.  
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To investigate whether additionally to the aminoterminus, cleavage was also 
occurring at the carboxyterminus of NM, we repeated the experiment and this time 
used the anti HA-tag antibody to detect fragments (Fig. 35A), as the HA-tag antibody 
epitope contains internal chymotrypsin digestion sites (Fig. 32B).  
 
 
 
 
 
Figure 35. Detection of full-length and mutant NM proteolytic digestion fragments with 
the anti-HA antibody. (A) Proteolytic digestion of cell lysates from N2a NM-HAagg clone 7A, 
∆ 1-39 clone 5D, ∆ 75-123 subclone 8H-23 and the corresponding soluble NM-HA 
expressing bulk cell lines. Cell lysates were treated with chymotrypsin at the indicated 
protease to total protein ratios or left untreated. For size comparison, full-length and mutant 
NM-HAagg and NM-HAsol samples were loaded on the same gel. NM was detected using mAb 
anti-HA. CHY: chymotrypsin. (B) Putative fragments of full-length and mutant NM after 
digestion with chymotrypsin. Arrowheads mark preferential chymotrypsin digestion sites. 
Dark grey: EcoRI restriction site, red: HA-tag. Numbers refer to amino acids. 
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Interestingly, digestion fragments of full-length and mutant NM-HAsol and NM-HAagg 
appeared in the same pattern as when detected with the M domain antibody, 
indicating that, with the exception of the QNR in full-length NM, the entire NM protein 
including the M domain is protected within the formed aggregates (Fig. 35B). 
Noticeable, as the HA-tag antibody is stronger compared to the M domain antibody it 
is able to detect even very weak fragments on the Western blot not visible with the M 
domain antibody. However, additional weak fragments detected on the Western blot 
for the aggregated full-length NM and NM mutant proteins coincide with fragments 
observed in cell lysates form the respective soluble isoforms and therefore most 
likely originate from residual soluble protein found in the N2a NM-HAagg cell 
populations.  
To analyze the structure of NM fibrils in comparison to endogenous full-length NM 
aggregates, we performed limited proteolytic digestion of in vitro fibrillized 
recombinant NM (Fig. 36).  
 
 
              
 
 
Figure 36. Limited proteolysis of recombinant NM fibrils. Western blot image of in vitro 
fibrillized recombinant NM that was digested with chymotrypsin at the indicated protease to 
total protein ratios or left untreated. NM was detected using 4A5 anti-M domain antibody. 
CHY: chymotrypsin. 
 
As expected, no partial proteolytic digestion pattern could be detected for the tightly 
packed recombinant NM fibrils, indicating strong structural differences between        
in vitro fibrillized and intracellularly aggregated NM.  
In summary, the results demonstrate that: (1) the proteolytic protected core region of 
full-length NM-HA aggregates does not include the QNR, (2) full-length NM-HA and 
NM-HA ∆ 1-39 likely share a similar core and (3) upon deletion of the last three 
oligopeptide repeats and the CTN (NM-HA ∆ 75-123), the protected region shifts 
towards the aminoterminus, now also including the QNR region. 
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4. Discussion 
 
Successful prion replication requires three sequential steps: de novo induction of 
prions, fragmentation of amyloid fibrils and transmission of infectious propagons to 
daughter cells, and, in the case of mammalian cells, to bystander cells (Cascarina 
and Ross 2014). In S. cerevisiae these processes depend on two domains within the 
N domain of NM. De novo induction of aggregates is facilitated by the QNR and the 
first two repeats of the OPR, whereas Hsp104 mediated fragmentation and 
subsequent maintenance of the aggregate phenotype requires the entire OPR (King 
2001, Parham et al. 2001, Osherovich et al. 2004, Shkundina et al. 2006). Here we 
demonstrate that, contrary to prion propagation in S. cerevisiae, the three sequential 
steps of prion replication and inheritance in the mammalian cell environment are 
encoded by only one region: the last three repeats of the OPR and the CTN           
(aa 75-123) (Fig. 37). Deletion of this region drastically impaired spontaneous 
formation of aggregates, initial aggregate induction and decoration as well as 
maintenance of aggregates. However, base levels of prion replication activity were 
still detected in mutants lacking this region, indicating that different types of 
aggregates can be formed, and once assembled, are capable of replication.  
 
4.1 Spontaneous aggregation is inhibited by the QNR in mammalian cells 
 
Although the exact structure of NM aggregates in N2a cells is not known, their ability 
to be seeded, their insolubility and SDS resistance strongly indicate the formation of 
amyloid fibrils. Though these characteristics are indicative of amyloid formation, 
further experiments could be performed to ensure the amyloidogenic nature of NM 
aggregates. Congo red staining is primarily used on histological sections to 
demonstrate the presence of amyloid fibrils, but was also successfully used in cell 
culture experiments (Sipe 1994, Kluve-Beckerman et al. 1999). While Thioflavin-T 
(ThT) can be used for histological stainings, it is also broadly used for in vitro 
analysis and immunofluorescence stainings of amyloid candidate proteins, as its 
fluorescence emission is strongly enhanced upon binding to amyloid fibrils 
(Biancalana and Koide 2010). 
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Figure 37. Summary of the results. Spontaneous aggregation, fibril-mediated induction of 
aggregates and aggregate maintenance were studied in N2a cell lines stably expressing    
full-length NM or NM mutants with a carboxyterminal HA-tag. To investigate the propensity to 
decorate endogenous NM aggregates, N2a cell line 2CG11 producing stable NM-GFP prions 
was transfected with HA-tagged full-length NM and NM mutant constructs. Transmission to 
bystander cells was assessed using stable full-length and mutant NM aggregate-bearing cell 
clones cocultured with soluble NM-GFP expressing N2a cells. Decoration: ''++'' decoration of 
endogenous aggregates was detected in ≥ 50% transfectants, ''+'' in ≤ 5% transfectants,      
''-'' in ≤ 1 % transfectants. Aggregate maintenance: ''++++'' slightly increased mitotic stability 
compared to the full-length NM control (fold change > - 0.5 and < 0), ''+++'' only slightly 
impaired mitotic stability (> 0 and < 0.5), ''++'' lower mitotic stability (> 0.5 and < 1), ''+'' very 
low mitotic stability (> 1 and < 1.5). Transmission to bystander cells: ''+'' transmission was 
observed in at least 103 cells, ''n.d.'' not done.  
 
Lately, it was proposed that in early events of amyloid formation, monomers group 
together to form micelle-like structures that are converted to the prion-isoform upon 
binding to insoluble seeds (Serio et al. 2000). This finding is supported by results of 
the group of Simon Alberti, which argue that formation of fibrous aggregates is 
preceded by protein assembly in liquid droplets (Patel et al. 2015). In vitro and in     
S. cerevisiae, interactions of NM monomers and interactions observed in peptide 
arrays, that would precede de novo aggregation, are mainly governed by amino acid 
stretches within the QNR, regions often referred to as nucleation sites (Krishnan and 
Lindquist 2005, Tessier and Lindquist 2007).  
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Interestingly, studies also identified a second region ranging from residues ~ 90-120, 
roughly including R5, R6, and the CTN, to be capable of forming intermolecular 
contacts, though interactions were found to be weaker compared to the first domain 
(Krishnan and Lindquist 2005, Tessier and Lindquist 2007). The subsequent step,   
de novo aggregation induced through overexpression of NM, is facilitated by the 
QNR and the first two repeats of the OPR, as identified by three separate studies 
(King 2001, Osherovich et al. 2004, Shkundina et al. 2006). In mammalian cells, 
spontaneous aggregation is comparable to de novo aggregation in yeast. 
Interestingly, in contrast to the previous findings in yeast, we found that in 
mammalian cells, spontaneous aggregation was in fact inhibited by the QNR and 
formation of aggregates was mainly promoted by the last three oligopeptide repeats 
and the CTN (aa 75-123) (Fig. 37). This suggests that de novo aggregation or 
spontaneous aggregation of NM can be facilitated by different nucleation sites in 
yeast and mammalian cells. Thus, the cellular environment is a factor that has to be 
taken into account when analyzing binding or aggregation behavior of prion or   
prion-like proteins. 
Compiling evidence argues that the amino acid composition is the major determinant 
of amyloid or prion propensity (Ross, Edskes, et al. 2005, Ross, Minton, et al. 2005, 
Shewmaker et al. 2008). At that time, multiple studies had already reported that 
glutamine and more recently, asparagine residues, promote aggregation (DePace et 
al. 1998, Michelitsch and Weissman 2000, Perutz et al. 2002, Peters and Huang 
2007, Alberti et al. 2009, Sabate et al. 2015). Interestingly, compared to the QNR, the 
region comprising the last three repeats and the CTN (aa 75-123) has a lower 
percentage of glutamine and asparagine residues (aa 75-123: 42.9 %, QNR: 55.3 %) 
as well as a lower N/Q ratio (aa 75-123: 0.62, QNR: 0.75) (Fig. 38). Additionally, the 
region encompassing residues 75-123 has a higher content of prolines compared to 
the QNR (aa 75-123: 8.2 %, QNR: 0 %). Proline residues have been reported to 
disfavor and even break β-sheets (Li et al. 1996, Adessi and Soto 2002, Lopez de la 
Paz and Serrano 2004) (Fig. 38). In an extensive in vivo assay Toombs and 
coworkers quantitatively assessed the compositional effects on prion formation 
(Toombs et al. 2010). They detected that charged residues strongly disfavor prion 
formation, whereas hydrophobic amino acids, with the exception of proline residues, 
strongly promote aggregation.  
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Figure 38. Amino acid composition of different deletion regions within the N domain. 
The position of the deletion regions and their lengths are depicted at the top in amino acid 
residues. The abundance of the individual residue is given in percent. 
 
Interestingly, the last three oligopeptide repeats and the CTN comprise an increased 
number of hydrophobic residues (30.5 %) compared to the QNR (18.4 %) 
(percentages without proline residues), and a slightly reduced number of charged 
residues (aa 75-123: 4 %, QNR: 5.2 %) (Fig. 38). Two factors that would increase the 
overall prion propensity of the region comprising the last three oligopeptide repeats 
and the CTN. Yet, taken together with the decreased amount of glutamine and 
asparagine residues and the increase in proline residues, in total both regions might 
be similarly prionogenic. The comparison of the most significant differences in amino 
acid composition shows that composition alone does not suffice to determine amyloid 
or prion propensity. Interestingly, Toombs and coworkers made a similar observation. 
Though some amino acids strongly promote prion formation, these residues were not 
abundantly present in the known yeast PrDs (Toombs et al. 2010). Therefore, they 
hypothesized that PrDs are not optimized for maximum prion forming propensity, 
instead their composition demonstrates a balance of intrinsic disorder and prion 
propensity (Toombs et al. 2010). 
 
Discussion 
 76 
In summary, these findings indicate that different nucleation sites are predominantly 
active in vitro and in S. cerevisiae compared to mammalian cells, and their position 
cannot sufficiently be determined by amino acid composition alone, environmental 
factors must be considered as well. 
 
4.2 Template-assisted aggregation is facilitated by the last three 
oligopeptide repeats and the CTN in mammalian cells 
 
In line with experiments performed in yeast, in mammalian cells the prion phenotype 
can also be induced by addition of exogenous seeds (Sparrer et al. 2000, King and 
Diaz-Avalos 2004, Tanaka et al. 2004, Krammer et al. 2009). Similar to spontaneous 
aggregation, also for template-assisted aggregate induction by recombinant NM 
fibrils the QNR played only a minor role and lowest induction rates were again 
observed when the last three repeats and/or the CTN were absent (aa 75-123)    
(Fig. 37). But even though aggregation was strongly impaired in these mutants, 
aggregate formation was not entirely abolished. This suggests that in the absence of 
the seemingly preferential site for template-assisted aggregation in mammalian cells 
(aa 75-123), alternative and less efficient binding sites take over. Our results show 
that aggregation is still possible even in NM mutant ∆ 39-123, encoding only the QNR 
in addition to the M domain. As already shown by our initial results, the M domain 
itself is not capable of aggregation, which suggests that alternative sites must lie 
within the first 38 residues of the N domain. As earlier discussed, regions within the 
QNR have already been identified as possible binding or nucleation sites (Krishnan 
and Lindquist 2005, Tessier and Lindquist 2007), strengthening our hypothesis that 
the QNR functions as an alternative binding site for template-assisted aggregation in 
mammalian cells. 
The last three repeats and/or the CTN were also crucial for decoration of pre-existing 
aggregates (Fig. 37). Interestingly, although in some cells aggregation could be 
induced in cell populations where the last three repeats and/or the CTN were deleted 
(≤ 5%), some aggregate puncta did not colocalize with endogenous NM-GFP prions. 
This suggests that even though NM-GFP aggregates can initially template the 
conversion into the prion isoform, aggregate conformations might differ between   
full-length NM and NM mutants lacking the last three repeats and/or the CTN. Yet, 
the strongest effect was observed when the entire OPR in addition to the CTN were 
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deleted (NM ∆ 39-123). Less than 1 % of cells showed NM-HA colocalization with 
NM-GFP prions. The virtual abolishment of coaggregation in this NM mutant, 
suggests that, in contrast to template-assisted aggregation by NM fibrils, the QNR is 
not sufficient to decorate pre-existing aggregates. This finding is consistent with the 
study by Osherovich and coworkers, who found that for decoration of pre-existing 
fibrils at least the first repeat in addition to the QNR (aa 1-57) was needed 
(Osherovich et al. 2004). Combined, these findings demonstrate that the last three 
repeats and the CTN are the preferential sites for template-assisted aggregation by 
NM fibrils and decoration of pre-existing aggregates in mammalian cells. However, in 
the absence of the preferential binding site, the QNR functions as an alternative 
binding site for aggregate induction by NM fibrils. This site is, however, insufficient to 
facilitate decoration of pre-existing aggregates. 
 
4.3 The last three oligopeptide repeats and the CTN contribute to prion 
maintenance in mammalian cells 
 
Multiple studies have demonstrated that the entire OPR is a crucial region for 
fragmentation and maintenance of the prion phenotype in yeast (Doel et al. 1994, 
Parham et al. 2001, Osherovich et al. 2004, Shkundina et al. 2006). In yeast, 
fragmentation is mediated by the Hsp104 machinery (Chernoff et al. 1995). Our 
studies on the contrary, have shown that in the mammalian cell environment 
aggregate maintenance predominantly depends on the last three repeats of the OPR 
and the CTN (aa 75-123). Additionally, so far no mammalian homologue of Hsp104 
has been identified (Chernoff et al. 1995), suggesting that fragmentation must be 
facilitated by different means in the mammalian cytosol. The independence of 
aggregate fragmentation from the aminoterminal OPR and Hsp104 is also reflected 
by the finding that the glycine to aspartic acid point mutation in the second repeat 
(G58D) improves prion maintenance compared to the full-length NM control. In yeast, 
NM G58D acts as a dominant-negative prion mutant that results in the elimination of 
the prion phenotype (Doel et al. 1994, Osherovich et al. 2004). The NM mutant was 
reported to destabilize the amyloid fiber and enhance Hsp104 mediated dissolution, 
leading to the observed defects in prion inheritance (DiSalvo et al. 2011). 
Interestingly, in yeast the G58D induced interference with the prion phenotype 
appears to be a strain dependent phenomenon, likely depending on the aggregate 
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structure of the individual variant (Derkatch et al. 1999, Verges et al. 2011). Our 
finding that G58D has no deteriorating effect on NM maintenance in mammalian 
cells, combined with the strain and conformation dependence observed in the NM 
mutant in yeast, implicate that NM conformers in mammalian cells differ from the 
predominant conformations in yeast. Thus, NM aggregates in mammalian cells, will 
subsequently also depend on different fragmentation machineries that have yet to be 
identified. 
 
4.4 NM infectivity is not governed by the QNR or the last three 
oligopetide repeats and the CTN in mammalian cells 
 
Prions in mammalian cells can infect neighboring cells and induce a self-perpetuating 
prion state. Yeast prions were already shown to be infectious in yeast as well as in 
mammalian cells (Wickner 1994, Hofmann et al. 2013). Yet, whether specific 
domains in NM contribute to the protein’s infectivity has not been analyzed so far. In 
our study, we found that neither deletion of the QNR nor deletion of the last three 
repeats and the CTN prevented the infection of neighboring cells (Fig. 37). Although 
induction rates were overall low, deletion of the QNR in fact significantly increased 
the appearance of NM aggregates in recipient cells, suggesting that the QNR has, if 
any, a rather inhibiting effect. Though one out of four clones harboring NM ∆ 75-123 
aggregates was not infectious, no difference to full-length NM could be detected in 
the quantitative assessment, suggesting that the last three repeats and the CTN do 
not contribute to NM infectivity. Notably, infectivity experiments were performed using 
cell clones, and it cannot be excluded that clonal differences had an effect on 
induction efficiencies. Additionally, it has to be considered that the analyzed clones 
were amongst other factors selected for the mitotic stability of NM aggregates, which 
necessitates successful fragmentation of high molecular weight conformers. 
Fragmentation on the other hand, is also a requirement to generate small infectious 
entities capable of entering neighboring cells. Therefore, in the cloning process 
selected NM mutant aggregates might not represent the true infectious efficiencies of 
the NM mutants. During the maintenance experiment and the cloning process, NM 
mutant ∆ 75-123 already showed mitotic instability that might have been facilitated 
through deficiencies in fragmentation. This likely also affected its infectious activities. 
However, one observation we made was that, regardless of the NM sequence, 
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overall clones with smaller, punctate aggregates appeared to have higher induction 
rates, indicating that at least for the analyzed clones, infectivity might have been 
sequence-independent. Combined, our findings indicate that NM infectivity is not 
governed by the QNR or the last three repeats and the CTN and follow-up 
experiments should be performed. 
 
4.5 Aggregation is facilitated through different nucleation sites in 
mammalian cells and in S. cerevisiae 
 
A striking feature of prions is the faithful propagation of strains or variants that induce 
distinct prion phenotypes. Prion variants have been proposed to differ in their 
conformations, resulting from variations in the length or position of the amyloid core 
and the extent of β-sheet structures (Tanaka et al. 2004, Toyama et al. 2007, Chang 
et al. 2008). In vitro fibrillized recombinant NM has been shown to contain a mixture 
of amyloid conformations (Glover et al. 1997, Gorkovskiy et al. 2014). Despite that 
great diversity, so far investigated variants in vitro as well as in yeast mostly 
contained amyloid core structures spanning the aminoterminal N domain including 
the QNR (Toyama et al. 2007, Luckgei et al. 2013). In our mammalian cell model, on 
the other hand, in vitro fibrillized NM induces full-length NM conformers, where the 
QNR is not part of the tightly packed, proteolytically protected core region. 
Interestingly, Chang and colleagues suggested that the successful propagation of a 
specific strain is affected by the genetic environment of the host and the biophysical 
properties of the strain (Chang et al. 2008). Thus, in vitro, in yeast and in the 
mammalian cell environment, different conformations might be dominant as a result 
of selective pressure. This notion agrees with two theories: (1) the mutational clone 
theory and (2) the ''cloud'' or ''ensemble'' model of prion variants (Collinge and Clarke 
2007, Li et al. 2010) (Fig. 39). In the mutational clone theory (Fig. 39, left panel), one 
prion variant undergoes mutational changes, whereby it adopts a different 
conformation and generates a new prion variant. In the ''cloud or ''ensemble'' model 
(Fig. 39, right panel), prion variants comprise a cloud of conformational species with 
one dominant and multiple less frequent conformers. Though several conformations 
coexist, only the predominant, abundant conformation will be detectable in 
biochemical analysis (Collinge and Clarke 2007).  
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Figure 39. Mutational clone theory vs. cloud or ensemble of prion variants. Two 
possible theories explaining the appearance of different conformers over time. In the 
mutational clone theory (left panel), one prion variant undergoes mutational changes, 
whereby a new distinct prion variant is generated. In the ''cloud'' or ''ensemble'' model of 
prion variants (right panel), prion variants exist as a cloud of conformational species with one 
dominant conformation and multiple low-copy number conformations that might be favored 
by another host or environment. 
 
However, under selective pressure in a different host or environment, another 
conformation might be favored and emerges. Although biochemical assays have 
shown that the mixture of in vitro fibrillized recombinant NM favors a conformation 
with the QNR as its amyloid core (Toyama et al. 2007, Luckgei et al. 2013), once 
introduced into the mammalian cell environment, conformational requirements 
appear to change and lead either to the interconversion into a fitter conformation or 
the selective amplification of a formerly low copy number conformer, most likely with 
the CTN as its nucleation site and core region. However, as previously discussed, 
NM mutant ∆ 39-123, with only the QNR in addition to the N domain, also shows 
weak levels of aggregation, indicating that a second conformation and thus 
nucleation site (QNR) can be active if the predominant one is absent (Fig. 40). The 
adaptation of a different conformation in the absence of the predominant nucleation 
site (CTN) was also observed in the limited proteolysis experiment digesting NM       
∆ 75-123.  
 
Discussion 
 81 
 
 
 
Figure 40. Putative model of NM prion nucleation and seeding. NM contains two putative 
nucleation sites. In the mammalian cytosol, the carboxyterminal nucleation site (CTN,          
aa 98-123) is favored and responsible for nucleation and template-assisted seeding (left 
panel). The aminoterminal nucleation site (QNR, aa 1-38) likely mediates assembly and 
seeding in the absence of the carboxyterminal site (right panel). 
 
In contrast to full-length NM, no fragmentation pattern was detected for NM ∆ 75-123, 
demonstrating that upon deletion of the last three repeats and the CTN, the amyloid 
conformation is altered and now also includes the QNR in its tightly packed core. 
Whether this second conformation with its alternative nucleation site can also be 
found for full-length NM in the mammalian environment, cannot be verified so far. 
However, the presence of two optional nucleation sites is already supported by two 
studies. Krishnan and Lindquist identified in 2005 two regions to form intermolecular 
contacts in mature NM fibrils (aa 25 - 38: head, aa 91 - 106: tail) (Krishnan and 
Lindquist 2005). In 2007, Tessier and colleagues identified regions spanning either 
residues 9-39 or 90-120 as self-nucleation elements using peptide arrays (Tessier 
and Lindquist 2007). Krishnan and Lindquist found that the intermolecular contacts 
were made in a head - head and tail - tail fashion and took this to be evidence for a 
β-helix amyloid fibril model, where each monomer runs along the fibril axis and forms 
contacts with the following monomer in an opposed orientation (Krishnan and 
Lindquist 2005). We, however, suggest that their finding is rather proof of the 
existence of two possible nucleation sites that separately arise under different 
environmental conditions. The interpretation of the results as evidence for a β-helix 
amyloid fibril model can also be called into question by the numerous studies 
showing proof for the in-register parallel β-sheet structure of NM fibrils (Shewmaker 
et al. 2006, Toyama et al. 2007, Shewmaker et al. 2009). Additionally, if two 
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nucleation sites were needed for a stable amyloid structure, deletion of one of the 
two should result in severe deficiencies in initial aggregate formation. However, the 
aggregation propensity of NM was not significantly altered by deletion of only the 
alternative, less favored nucleation site, as demonstrated in yeast (NM ∆ 98-123) as 
well in our study in mammalian cells (NM ∆ 1-39) (Osherovich et al. 2004, Shkundina 
et al. 2006). The suggestion that in yeast and in mammalian cells, two separate 
nucleation sites are predominantly active is also supported by an experiment 
conducted by our group in 2009 (Krammer et al. 2009). It was shown that induction of 
the prion phenotype in yeast with N2a NM-HAagg cell extracts is possible but results 
in a delayed induction time. The delay in induction time could be explained by either 
the mutational clone or the cloud/ensemble model, but either way would likely have 
resulted from the need for conformational alterations due to selective pressure of a 
new environment. 
 
4.6 PrionW accurately predicts the NM prion domain in mammalian cells 
 
In recent years, tremendous progress has been made towards understanding what 
differentiates prion from non-prion proteins (Alberti et al. 2009, Toombs et al. 2010). 
The majority of this research has been based on Q/N rich prion proteins and their 
prionogenic behavior in vitro as well as in yeast. Whether, however, the same factors 
or parameters will drive prion formation in the mammalian cytosol has not yet been 
elucidated. Nevertheless, our group already showed that NM is capable of replicating 
in our mammalian cell model, demonstrating that the mammalian cytosol is capable 
of replicating Q/N rich prions. With the newly found knowledge on amyloidogenic and 
prionogenic behavior in yeast, algorithms have been trained to discover so far 
unknown prion and prion-like proteins. Though algorithms have been vastly 
improving, they are far from optimal yet. To discriminate between prion and non-prion 
proteins, two major theories have been put forward. In the first theory, amyloid 
formation is driven by many weak interactions that are located in a long disordered 
region. In the second theory, a short amyloidogenic, often hydrophobic amino acid 
region initially seeds amyloid formation. Algorithms like PLAAC (prion-like amino acid 
composition), PAPA (prion aggregation prediction algorithm) and PrionScan fall in the 
first group of prediction algorithms and define almost the entire N domain (PLAAC, 
PAPA), or in the case of PrionScan, residues 5-65, as a region with high prion 
propensity (Table 9).  
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Table 9: Disorder, β-aggregation, amyloid and prion prediction algorithms 
 
Name 
(Prediction) 
Description Reference 
Result for 
NM (aa) 
FoldIndex 
(Disorder) 
Uses the algorithm by Uversky and 
colleagues to predict if a protein sequence 
is intrinsically disordered that is based on 
its average residue hydrophobicity and net 
charge. 
Uversky et al. (2000) 
Prilusky et al. (2005) 
http://bip.weizmann.ac.
il/fldbin/findex 
1-250 
Zyggregator 
(β-
aggregation) 
A sequence-based algorithm that predicts 
the aggregation propensity of proteins 
based on their hydrophobicity, charge and 
propensity to form β-sheet structures as 
well as environmental factors. 
DuBay et al. (2004) 
Pawar et al. (2005) 
Tartaglia et al. (2008) 
http://www-mvsoftw 
are.ch.cam.ac.uk/ 
Domains          
> 2 aa: 
45-55, 
102-107 
Waltz 
(Amyloids) 
Position-specific scoring matrix based on 
the structural and biophysical analysis of 
over 200 amyloid forming or non-forming 
hexapeptides, to identify sequences with a 
high propensity to nucleate amyloid 
formation. 
Maurer-Stroh et al. 
(2010) 
http://waltz.switchlab.o
rg/ 
9-18,        
31-36,      
45-56,      
69-74,    
102-108 
pWaltz, 
PrionW 
(Prions) 
Identification of PrDs that fulfill three 
requirements: (1) contain a protein stretch 
with significant prion propensity (pWaltz), 
(2) have a disordered structure (FoldIndex),         
(3) have an amino acid composition that 
allows the protein to retain its soluble state 
but still exhibit amyloid propensity scored 
by Sabate et al. (2015). 
Sabate et al. (2015) 
Zambrano et al. (2015) 
http://bioinf.uab.cat/pri
onw/ 
98-118 
 
Alberti et al., 
PLAAC 
(Prions) 
Uses a hidden Markov model to identify 
prion-like sequences, at least 60 amino 
acids long, based on compositional 
similarities to four known yeast PrDs. 
Alberti et al. (2009) 
Lancaster et al. (2014) 
http://plaac.wi.mit.edu/ 
~ 1-133 
 
PAPA 
(Prions) 
The algorithm determines the overall prion 
propensity of a protein by calculating the 
prion propensity of a sliding 41 amino acid 
window based on the prion propensity 
score of each amino acid and the negative 
FoldIndex of the region (score for disorder). 
Toombs et al. (2010) 
Toombs et al. (2012) 
http://combi.cs.colostat
e.edu/supplements/pa
pa/ 
~  1-100 
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The PLAAC algorithm uses a hidden Markov model (HMM) to identify potential prions 
and analyzes their sequences for PrLDs and non-PrLDs (Lancaster et al. 2014). The 
analysis is based on findings by Alberti and colleagues who determined amino acid 
frequencies of PrDs of the four best-known prions of S. cerevisiae (including Sup35) 
(Alberti et al. 2009). PAPA, on the other hand, is based on an extensive in vivo study 
that quantitatively assigns prion propensity scores to each amino acid (Toombs et al. 
2010, Toombs et al. 2012). The algorithm scans the protein sequence and 
determines prion propensity based on the overall score of the amino acids and 
regions of disorder (FoldIndex) (Prilusky et al. 2005). PrionScan uses a 
computational strategy to predict prion proteins that is also based on compositional 
similarities to yeast prions using the Alberti data set (Alberti et al. 2009, Espinosa 
Angarica et al. 2013, Espinosa Angarica et al. 2014). In contrast to other algorithms, 
PrionScan aims to present a database where all protein sequences in public 
databases are analyzed for putative PrLDs. To this end, the database is constantly 
updated based on the update of UniprotKB. Zyggregator, Waltz and its updated prion 
prediction algorithm pWaltz (prionW), on the other hand, fall into the second group 
and predict regions ≤ 21 residues (Table 9). Zyggregator is a sequenced-based 
algorithm that generates an aggregation profile of protein sequences based on the 
physicochemical properties of the amino acids including hydrophobicity, charge and 
propensity to fold into β-sheets (DuBay et al. 2004, Pawar et al. 2005, Tartaglia et al. 
2008). PrionW is a web application that analyzes protein sequences for PrDs based 
on three parameters. First, the sequence is screened for large, disordered regions 
using FoldIndex (Prilusky et al. 2005). Secondly, disordered regions are analyzed for 
their Q/N content with the default threshold set to 25 %. In the last step, remaining 
PrionScan 
(Prions) 
The model uses the statistical significance 
of the prion propensity of amino acids 
obtained by analyzing 29 proteins 
experimentally tested as prions and 18 
proteins that did not show prion 
characteristics defined by Alberti et al. 
(2009). The program runs a 60 residue 
window over the amino acid sequence 
identifying potential PrLDs with a 
statistically determined cutoff at 50. 
Espinosa Angarica et 
al. (2013) 
Espinosa Angarica et 
al. (2014) 
http://webapps.bifi.es/p
rionscan 
5-65 
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sequences are screened for PrDs using the pWaltz algorithm, an updated version of 
the previous Waltz algorithm to specifically detect prion rather than only 
amyloidogenic domains (Maurer-Stroh et al. 2010, Sabate et al. 2015, Zambrano et 
al. 2015). Comparing the outcomes of the algorithms with our experimental results, 
we found that prionW (aa 98-118) closely predicted our experimentally validated PrD 
in mammalian cells (aa 98-123) (Fig. 41).  
 
 
 
 
 
Figure 41. Results of a selection of prediction algorithms analyzing full-length NM. 
Predictions of disorder (FoldIndex), β-aggregation propensity (Zyggregator), prion propensity 
(PAPA, PLAAC) and PrD's (prionW). Images were designed using the PLAAC and 
Zyggregator web applications. Dotted red lines indicate individual thresholds of the 
algorithms: FoldIndex: < 0; PAPA; > 0.1; PLAAC: > 0, Zyggregator: > 1. The region identified 
as PrD by prionW is shown at the bottom.  
 
This suggests that in the mammalian cell environment, the combination of a short 
region with a high prion propensity that is embedded in a larger disordered Q/N rich 
region is best suited to predict our PrD. Although prionW accurately predicts the PrD 
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active in NM in mammalian cells, it still has to be seen if it will successfully predict 
PrDs of to date unknown prion candidates. However, the emergence of a novel prion 
variant in mammalian cells, demonstrates that the dissection of structural elements 
that govern prion propensities has to be undertaken in the correct environment to 
further refine prediction algorithms and detect so far unknown prion or prion-like 
proteins that are active in mammalian cells. 
 
4.7 The emergence of prion-like proteins 
 
Tartaglia and coworkers have suggested that many proteins have coevolved with 
quality-control mechanisms in their cellular environment to retain their functional 
soluble state, but only few alterations can tip the scale towards becoming 
aggregation-prone (Tartaglia et al. 2007). This theory was later confirmed by Ross 
and colleagues, who demonstrated that only a few mutations can turn formally             
non-aggregating into aggregating proteins and in two incidents into proteins with 
prion activity (Paul et al. 2015). To date, an increasing number of proteins connected 
to neurodegenerative diseases has been proposed to have prion-like properties. 
Among these are proteins like TDP-43, FUS and TAF-15 that underlie diseases such 
as ALS and FTLD (King et al. 2012). TDP-43 is mainly found in the nucleus but also 
shuttles back and forth between nucleus and cytoplasm (Ayala et al. 2008). It 
functions in transcriptional regulation and splicing of RNA (Buratti and Baralle 2008, 
Buratti and Baralle 2010, King et al. 2012). TDP-43 contains a PrLD at its 
carboxyterminus and was shown to form cytoplasmic inclusions in FTLD and ALS 
(Brandmeir et al. 2008, Pamphlett et al. 2009). In vitro, full-length TDP-43 is 
intrinsically aggregation-prone, but aggregation can be prevented upon deletion of its 
PrLD that was shown to eliminate the protein's toxicity in several model systems 
(King et al. 2012). Several mutations linked to ALS were found within the PrLD of 
TDP-43 that increase its toxicity (Johnson et al. 2009). Similar to TDP-43, FUS is 
predominantly a nuclear protein that shuttles in and out of the nucleus and is 
responsible for transcriptional regulation and RNA homeostasis (Bertolotti et al. 1996, 
Zinszner et al. 1997, Kasyapa et al. 2005, King et al. 2012). FUS inclusions were 
found in the cytoplasm of ALS and FTLD patients (Kwiatkowski et al. 2009, Vance et 
al. 2009, Neumann et al. 2011). FUS contains a PrLD at its aminoterminus that is 
strongly aggregation-prone (Couthouis et al. 2011, Sun et al. 2011). Deletion of its 
PrLD prevents FUS from aggregating (Sun et al. 2011). TAF-15 is a nuclear protein 
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associated with the transcription factor II D complex and RNA polymerase II (Tan and 
Manley 2009). TAF-15 contains a PrLD at its aminoterminus, is aggregation-prone 
and found to be aggregated in the cytoplasm of ALS and FTLD patients (Couthouis 
et al. 2011, Neumann et al. 2011). All three proteins form cytoplasmic inclusions in 
neurodegenerative diseases, and were now shown to contain PrLDs. This 
demonstrates that to date prediction algorithms can already detect proteins that show 
prion-like properties in the mammalian cytosol. However, as previously discussed, 
algorithms are still far from optimal and many prion-like proteins remain undetected. 
Yet, the achievements so far show the possibilities that functional algorithms can 
offer and simultaneously demonstrate the need for continuous refinement of the 
prediction qualities to detect so far unknown prion and prion-like proteins. 
 
4.8 Relevance 
 
The field of prion research has been vastly developing with the discovery of yeast 
prions and it was through the investigation of yeast prions that the existence of PrDs 
was discovered. PrDs are modular regions within a protein sequence that govern the 
propensities required for successful prion replication. The discovery of PrDs that 
carry the crucial elements for prion behavior led to the development of numerous 
prion prediction algorithms aiming to identify so far unknown prion proteins in a 
genome wide search. Recently, as much as one percent of human protein-coding 
genes have been proposed to contain PrLDs. Among these, some have already been 
connected to neurodegenerative diseases like ALS and FTLD. However, up to this 
point, algorithms were designed based on the prionogenic behavior of proteins in 
either lower eukaryotes or in vitro. Yet, our results have shown that the environment 
plays a crucial role in determining the active prion variant and has to be taken into 
account in the continual optimization of prediction algorithms. Therefore, a profound 
knowledge of the compositional requirements that facilitate prion replication in 
mammalian cells is crucial to identify prion or prion-like proteins that may underlie 
diseases of so far unknown etiology in mammals.  
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% Percent 
°C Degree Celsius 
∆ Deletion 
aa Amino acid 
AD Alzheimer’s disease 
ALS Amyotrophic lateral sclerosis 
ATCC American type culture selection 
BSA Bovine serum albumin 
BSE Bovine spongiform encephalopathy 
CHY Chymotrypsin 
CJD Creutzfeldt-Jakob disease 
CNS Central nervous system 
conj. Conjugated 
CPEB Cytoplasmic polyadenylation element binding protein 
CTN Carboxyterminal N domain 
ctrl Control 
CWD Chronic wasting disease 
DMEM Dulbecco's modified eagle's medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
E.coli Escherichia coli 
ECL Enhanced chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
ER Endoplasmic reticulum 
et al. And others ('' et alia'') 
FCS Fetal calf serum 
FFI Fatal familial insomnia 
Fig. Figure 
FTLD Frontotemporal lobar degeneration 
g Gram 
GFP Green fluorescent protein 
Glc Glycosylated 
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GPI Glycosylphosphatidylinositol 
GSS Gerstmann-Sträussler-Scheinker syndrome 
h Hour 
H2Obidest Bidistilled water 
HA Hemagglutinin 
HBSS Hank's balanced salt solution 
HC Hydrophobic core region 
Hek293T/17 Human embryonic kidney cells, expressing simian virus 40 large T 
antigen, clone 17 
HRP Horseradish peroxidase 
Hsp Heat shock protein 
IF Immunofluorescence 
Ig Immunoglobulin 
IMDM Iscove's modified Dulbecco's medium 
IPTG Isopropyl-β-D-thiogalactopyranoside 
kb Kilobase 
kDa Kilodalton 
l Litre 
LB Lysogeny broth 
M Molar concentration 
mA Milliampere (10-3) 
mAb Monoclonal antibody 
min Minute 
ml Milliliter (10-3) 
mM Millimolar concentration (10-3) 
N Asparagine 
n.d. Not done 
N2a Murine neuroblastoma cell line 
ng Nanogram (10-9) 
nm Nanometer (10-9) 
NM NM domain of Sup35 
NMagg Aggregated NM protein 
NMsol Soluble NM protein 
ns Not significant 
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O/N Overnight 
OD Optical density 
OPR Oligopeptide repeat region 
pAb Polyclonal antibody 
PAGE Polyacrylamide gel electrophoresis 
PAPA Prion aggregation prediction algorithm 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PD Parkinson’s disease 
PEG Polyethylene glycol 
PLAAC Prion-like amino acid composition 
PMCA Protein misfolding cyclic amplification 
PMD Protein misfolding disease 
PrD Prion domain 
PrLD Prion-like domain 
PRNP Gene of the human prion protein 
PrP Prion protein 
PrPC Cellular isoform of the prion protein 
PrPSc Pathogenic isoform of the prion protein 
Q Glutamine 
QNR Asparagine- and glutamine- rich region 
RNA Ribonucleic acid 
rpm Revolutions per minute 
RT Room temperature 
S. cerevisiae Saccharomyces cerevisiae 
SD Standard deviation 
SDD-AGE Semi-denaturing detergent - agarose gel electrophoresis 
SDS Sodium dodecyl sulfate 
sec Second 
SP Signal peptide 
TDP-43 43 kDa, transactive response DNA binding protein 
ThT Thioflavin-T 
Tris Tris(hydroxymethyl)aminomethane 
TSE Transmissible spongiform encephalopathy 
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UV Ultraviolet 
V Volt 
WB Western blot 
µg Microgram (10-6) 
µl Microlitre (10-6) 
µm Micrometer (10-6) 
µM Micromolar concentration (10-6) 
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